| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000001 (PRS77_BC) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Breast cancer | breast carcinoma | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000001/ScoringFiles/PGS000001.txt.gz |
| PGS000002 (PRS77_ERpos) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000002/ScoringFiles/PGS000002.txt.gz |
| PGS000003 (PRS77_ERneg) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000003/ScoringFiles/PGS000003.txt.gz |
| PGS000004 (PRS313_BC) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Breast cancer | breast carcinoma | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000004/ScoringFiles/PGS000004.txt.gz | |
| PGS000005 (PRS313_ERpos) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000005/ScoringFiles/PGS000005.txt.gz | |
| PGS000006 (PRS313_ERneg) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000006/ScoringFiles/PGS000006.txt.gz | |
| PGS000007 (PRS3820_BC) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Breast cancer | breast carcinoma | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000007/ScoringFiles/PGS000007.txt.gz | |
| PGS000008 (PRS3820_ERpos) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000008/ScoringFiles/PGS000008.txt.gz | |
| PGS000009 (PRS3820_ERneg) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000009/ScoringFiles/PGS000009.txt.gz | |
| PGS000015 (GPS_BC) |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Breast cancer | breast carcinoma | 5,218 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000015/ScoringFiles/PGS000015.txt.gz | |
| PGS000028 (PRS) |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Breast cancer | breast carcinoma | 83 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000028/ScoringFiles/PGS000028.txt.gz |
| PGS000029 (PRS_AS) |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Breast cancer | breast carcinoma | 76 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000029/ScoringFiles/PGS000029.txt.gz |
| PGS000045 (BCPRS_Overall) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Breast cancer | breast carcinoma | 88 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000045/ScoringFiles/PGS000045.txt.gz |
| PGS000046 (BCPRS_ER+) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Estrogen receptor [ER]-positive breast cancer | estrogen-receptor positive breast cancer | 87 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000046/ScoringFiles/PGS000046.txt.gz |
| PGS000047 (BCPRS_ER-) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Estrogen receptor [ER]-negative breast cancer | estrogen-receptor negative breast cancer | 53 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000047/ScoringFiles/PGS000047.txt.gz |
| PGS000050 (PRS44) |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Breast cancer | breast carcinoma | 44 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000050/ScoringFiles/PGS000050.txt.gz |
| PGS000051 (PRS67) |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Breast cancer | breast carcinoma | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000051/ScoringFiles/PGS000051.txt.gz |
| PGS000052 (sPRS161) |
PGP000037 | Lakeman IMM et al. J Med Genet (2019) |
Breast cancer | breast carcinoma | 161 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000052/ScoringFiles/PGS000052.txt.gz | |
| PGS000072 (CC_Breast) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Breast cancer | breast carcinoma | 187 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000072/ScoringFiles/PGS000072.txt.gz |
| PGS000119 (BCC32) |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Basal cell carcinoma | basal cell carcinoma | 32 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000119/ScoringFiles/PGS000119.txt.gz |
| PGS000153 (cGRS_Breast) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Breast cancer | breast carcinoma | 66 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000153/ScoringFiles/PGS000153.txt.gz |
| PGS000212 (PRS330_LumA) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal A-like) | luminal A breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000212/ScoringFiles/PGS000212.txt.gz |
| PGS000213 (PRS330_LumBHER2neg) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | HER2 negative breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000213/ScoringFiles/PGS000213.txt.gz |
| PGS000214 (PRS330_LumB) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal B-like) | luminal B breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000214/ScoringFiles/PGS000214.txt.gz |
| PGS000215 (PRS330_HER2) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (HER2-enriched-like) | HER2 Positive Breast Carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000215/ScoringFiles/PGS000215.txt.gz |
| PGS000216 (PRS330_TN) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (triple negative) | triple-negative breast cancer | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000216/ScoringFiles/PGS000216.txt.gz |
| PGS000317 (PRS180) |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Breast cancer | breast carcinoma | 180 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000317/ScoringFiles/PGS000317.txt.gz |
| PGS000332 (PRS_BC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Breast cancer | breast carcinoma | 6,390,808 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000332/ScoringFiles/PGS000332.txt.gz | |
| PGS000335 (BC_PRSCS) |
PGP000102 | Mars N et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 1,079,089 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000335/ScoringFiles/PGS000335.txt.gz |
| PGS000339 (PRS22_CM) |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Cutaneous melanoma | cutaneous melanoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000339/ScoringFiles/PGS000339.txt.gz | |
| PGS000341 (GRS33_SSc) |
PGP000110 | Bossini-Castillo L et al. Ann Rheum Dis (2020) |
Systemic sclerosis | systemic scleroderma | 33 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000341/ScoringFiles/PGS000341.txt.gz | |
| PGS000344 (PRS287_BC) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000344/ScoringFiles/PGS000344.txt.gz | |
| PGS000345 (PRS229_BC) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 229 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000345/ScoringFiles/PGS000345.txt.gz | |
| PGS000346 (PRS287_ERneg) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000346/ScoringFiles/PGS000346.txt.gz | |
| PGS000347 (PRS287_ERpos) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000347/ScoringFiles/PGS000347.txt.gz | |
| PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,103,220 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000398/ScoringFiles/PGS000398.txt.gz | |
| PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000399/ScoringFiles/PGS000399.txt.gz | |
| PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000400/ScoringFiles/PGS000400.txt.gz | |
| PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000401/ScoringFiles/PGS000401.txt.gz | |
| PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 389 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000402/ScoringFiles/PGS000402.txt.gz | |
| PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 16,316 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000403/ScoringFiles/PGS000403.txt.gz | |
| PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000404/ScoringFiles/PGS000404.txt.gz | |
| PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000405/ScoringFiles/PGS000405.txt.gz | |
| PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 292 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000406/ScoringFiles/PGS000406.txt.gz | |
| PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 3,166 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000407/ScoringFiles/PGS000407.txt.gz | |
| PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 108 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000433/ScoringFiles/PGS000433.txt.gz | |
| PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000434/ScoringFiles/PGS000434.txt.gz | |
| PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 446 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000435/ScoringFiles/PGS000435.txt.gz | |
| PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 16,626 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000436/ScoringFiles/PGS000436.txt.gz | |
| PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 63 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000437/ScoringFiles/PGS000437.txt.gz | |
| PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000438/ScoringFiles/PGS000438.txt.gz | |
| PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 467 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000439/ScoringFiles/PGS000439.txt.gz | |
| PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 2,111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000440/ScoringFiles/PGS000440.txt.gz | |
| PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 77 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000441/ScoringFiles/PGS000441.txt.gz | |
| PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000442/ScoringFiles/PGS000442.txt.gz | |
| PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 177 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000443/ScoringFiles/PGS000443.txt.gz | |
| PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 7,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000444/ScoringFiles/PGS000444.txt.gz | |
| PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000445/ScoringFiles/PGS000445.txt.gz | |
| PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000446/ScoringFiles/PGS000446.txt.gz | |
| PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 72 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000447/ScoringFiles/PGS000447.txt.gz | |
| PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 183 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000448/ScoringFiles/PGS000448.txt.gz | |
| PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,073,162 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000449/ScoringFiles/PGS000449.txt.gz | |
| PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000450/ScoringFiles/PGS000450.txt.gz | |
| PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 2,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000451/ScoringFiles/PGS000451.txt.gz | |
| PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000452/ScoringFiles/PGS000452.txt.gz | |
| PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000453/ScoringFiles/PGS000453.txt.gz | |
| PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000454/ScoringFiles/PGS000454.txt.gz | |
| PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000455/ScoringFiles/PGS000455.txt.gz | |
| PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000456/ScoringFiles/PGS000456.txt.gz | |
| PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000457/ScoringFiles/PGS000457.txt.gz | |
| PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 23 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000458/ScoringFiles/PGS000458.txt.gz | |
| PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 24 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000459/ScoringFiles/PGS000459.txt.gz | |
| PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000469/ScoringFiles/PGS000469.txt.gz | |
| PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000470/ScoringFiles/PGS000470.txt.gz | |
| PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000471/ScoringFiles/PGS000471.txt.gz | |
| PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000472/ScoringFiles/PGS000472.txt.gz | |
| PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000473/ScoringFiles/PGS000473.txt.gz | |
| PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 68 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000474/ScoringFiles/PGS000474.txt.gz | |
| PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 30,041 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000475/ScoringFiles/PGS000475.txt.gz | |
| PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 32 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000476/ScoringFiles/PGS000476.txt.gz | |
| PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000477/ScoringFiles/PGS000477.txt.gz | |
| PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 120 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000478/ScoringFiles/PGS000478.txt.gz | |
| PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,267 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000479/ScoringFiles/PGS000479.txt.gz | |
| PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000480/ScoringFiles/PGS000480.txt.gz | |
| PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000481/ScoringFiles/PGS000481.txt.gz | |
| PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000482/ScoringFiles/PGS000482.txt.gz | |
| PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 4,047 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000483/ScoringFiles/PGS000483.txt.gz | |
| PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 25 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000484/ScoringFiles/PGS000484.txt.gz | |
| PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000485/ScoringFiles/PGS000485.txt.gz | |
| PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000486/ScoringFiles/PGS000486.txt.gz | |
| PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000487/ScoringFiles/PGS000487.txt.gz | |
| PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 79 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000488/ScoringFiles/PGS000488.txt.gz | |
| PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000489/ScoringFiles/PGS000489.txt.gz | |
| PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000490/ScoringFiles/PGS000490.txt.gz | |
| PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000491/ScoringFiles/PGS000491.txt.gz | |
| PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000492/ScoringFiles/PGS000492.txt.gz | |
| PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 217 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000493/ScoringFiles/PGS000493.txt.gz | |
| PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000494/ScoringFiles/PGS000494.txt.gz | |
| PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,866 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000495/ScoringFiles/PGS000495.txt.gz | |
| PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41,744 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000496/ScoringFiles/PGS000496.txt.gz | |
| PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000497/ScoringFiles/PGS000497.txt.gz | |
| PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000498/ScoringFiles/PGS000498.txt.gz | |
| PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000499/ScoringFiles/PGS000499.txt.gz | |
| PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000500/ScoringFiles/PGS000500.txt.gz | |
| PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,142 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000501/ScoringFiles/PGS000501.txt.gz | |
| PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 747 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000502/ScoringFiles/PGS000502.txt.gz | |
| PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 61,635 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000503/ScoringFiles/PGS000503.txt.gz | |
| PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 148,560 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000504/ScoringFiles/PGS000504.txt.gz | |
| PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000505/ScoringFiles/PGS000505.txt.gz | |
| PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000506/ScoringFiles/PGS000506.txt.gz | |
| PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000507/ScoringFiles/PGS000507.txt.gz | |
| PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000508/ScoringFiles/PGS000508.txt.gz | |
| PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 3,038 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000509/ScoringFiles/PGS000509.txt.gz | |
| PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,682 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000510/ScoringFiles/PGS000510.txt.gz | |
| PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 118,388 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000511/ScoringFiles/PGS000511.txt.gz | |
| PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 286,144 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000512/ScoringFiles/PGS000512.txt.gz | |
| PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000513/ScoringFiles/PGS000513.txt.gz | |
| PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,237 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000514/ScoringFiles/PGS000514.txt.gz | |
| PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 84 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000515/ScoringFiles/PGS000515.txt.gz | |
| PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 6,977 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000516/ScoringFiles/PGS000516.txt.gz | |
| PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000517/ScoringFiles/PGS000517.txt.gz | |
| PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000518/ScoringFiles/PGS000518.txt.gz | |
| PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,376 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000519/ScoringFiles/PGS000519.txt.gz | |
| PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,435 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000520/ScoringFiles/PGS000520.txt.gz | |
| PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000521/ScoringFiles/PGS000521.txt.gz | |
| PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000522/ScoringFiles/PGS000522.txt.gz | |
| PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 270 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000523/ScoringFiles/PGS000523.txt.gz | |
| PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,708 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000524/ScoringFiles/PGS000524.txt.gz | |
| PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000525/ScoringFiles/PGS000525.txt.gz | |
| PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000526/ScoringFiles/PGS000526.txt.gz | |
| PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,436 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000527/ScoringFiles/PGS000527.txt.gz | |
| PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000528/ScoringFiles/PGS000528.txt.gz | |
| PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 310 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000529/ScoringFiles/PGS000529.txt.gz | |
| PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 174 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000530/ScoringFiles/PGS000530.txt.gz | |
| PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 98,026 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000531/ScoringFiles/PGS000531.txt.gz | |
| PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 12,277 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000532/ScoringFiles/PGS000532.txt.gz | |
| PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000533/ScoringFiles/PGS000533.txt.gz | |
| PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000534/ScoringFiles/PGS000534.txt.gz | |
| PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,484 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000535/ScoringFiles/PGS000535.txt.gz | |
| PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,546 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000536/ScoringFiles/PGS000536.txt.gz | |
| PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 363 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000537/ScoringFiles/PGS000537.txt.gz | |
| PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 85 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000538/ScoringFiles/PGS000538.txt.gz | |
| PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,356 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000539/ScoringFiles/PGS000539.txt.gz | |
| PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 7,118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000540/ScoringFiles/PGS000540.txt.gz | |
| PGS000730 (PRS_BCC) |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Basal cell carcinoma | basal cell carcinoma | 47 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000730/ScoringFiles/PGS000730.txt.gz |
| PGS000738 (CONFIRMED_PGS) |
PGP000145 | Roberts GHL et al. Am J Hum Genet (2019) |
Vitiligo | Vitiligo | 48 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000738/ScoringFiles/PGS000738.txt.gz |
| PGS000760 (VIT) |
PGP000164 | Khan Z et al. Nat Commun (2021) |
Vitiligo | Vitiligo | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000760/ScoringFiles/PGS000760.txt.gz | |
| PGS000766 (PRS56_CM) |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Cutaneous melanoma | cutaneous melanoma | 56 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000766/ScoringFiles/PGS000766.txt.gz |
| PGS000773 (PRS179_BC) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Breast cancer | breast carcinoma | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000773/ScoringFiles/PGS000773.txt.gz |
| PGS000774 (PRS179_ERpos) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000774/ScoringFiles/PGS000774.txt.gz |
| PGS000775 (PRS179_ERneg) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000775/ScoringFiles/PGS000775.txt.gz |
| PGS000783 (CC_Breast_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 162 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000783/ScoringFiles/PGS000783.txt.gz |
| PGS000873 (SNP143) |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Breast cancer | breast carcinoma | 143 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000873/ScoringFiles/PGS000873.txt.gz |
| PGS000927 (GBE_HC1158) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Other dermatitis (time-to-event) | dermatitis | 242 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000927/ScoringFiles/PGS000927.txt.gz |
| PGS000944 (GBE_HC261) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Eczema, dermatitis | Eczematoid dermatitis, dermatitis |
598 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000944/ScoringFiles/PGS000944.txt.gz |
| PGS000963 (GBE_HC1184) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Follicular cysts of skin and subcutaneous tissue (time-to-event) | Follicular Cyst | 264 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000963/ScoringFiles/PGS000963.txt.gz |
| PGS001011 (GBE_HC534) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Viral warts (time-to-event) | common wart | 5 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001011/ScoringFiles/PGS001011.txt.gz |
| PGS001040 (GBE_cancer1060) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Non melanoma skin cancer | non-melanoma skin carcinoma | 1,610 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001040/ScoringFiles/PGS001040.txt.gz |
| PGS001041 (GBE_cancer1003) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Skin cancer | skin carcinoma | 1,298 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001041/ScoringFiles/PGS001041.txt.gz |
| PGS001131 (GBE_HC530) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Zoster [herpes zoster] (time-to-event) | Herpes Zoster | 82 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001131/ScoringFiles/PGS001131.txt.gz |
| PGS001140 (GBE_HC1190) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Seborrheic keratosis (time-to-event) | seborrheic keratosis | 1,368 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001140/ScoringFiles/PGS001140.txt.gz |
| PGS001257 (GBE_INI1737) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Childhood sunburn | sunburn | 519 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001257/ScoringFiles/PGS001257.txt.gz |
| PGS001312 (GBE_HC38) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Psoriasis | psoriasis | 204 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001312/ScoringFiles/PGS001312.txt.gz |
| PGS001313 (GBE_HC1159) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Psoriasis (time-to-event) | psoriasis | 578 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001313/ScoringFiles/PGS001313.txt.gz |
| PGS001336 (GBE_cancer1002) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Breast cancer | breast carcinoma | 555 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001336/ScoringFiles/PGS001336.txt.gz |
| PGS001536 (GBE_HC1188) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Vitiligo (time-to-event) | Vitiligo | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001536/ScoringFiles/PGS001536.txt.gz |
| PGS001773 (PRS_atopicDermatitis) |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Moderate-to-severe atopic dermatitis | atopic eczema | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001773/ScoringFiles/PGS001773.txt.gz |
| PGS001778 (PRS15_BC) |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Breast cancer | breast carcinoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001778/ScoringFiles/PGS001778.txt.gz | |
| PGS001803 (portability-PLR_172) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Skin cancer | skin carcinoma | 4,371 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001803/ScoringFiles/PGS001803.txt.gz |
| PGS001804 (portability-PLR_174.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Breast cancer (female) | breast carcinoma | 2,984 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001804/ScoringFiles/PGS001804.txt.gz |
| PGS001869 (portability-PLR_681) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Superficial cellulitis and abscess | cellulitis | 131 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001869/ScoringFiles/PGS001869.txt.gz |
| PGS001871 (portability-PLR_696.4) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Psoriasis | psoriasis | 264 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001871/ScoringFiles/PGS001871.txt.gz |
| PGS001872 (portability-PLR_697) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Sarcoidosis | skin sarcoidosis | 79 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001872/ScoringFiles/PGS001872.txt.gz |
| PGS001873 (portability-PLR_704) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Diseases of hair and hair follicles | disorder of pilosebaceous unit | 461 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001873/ScoringFiles/PGS001873.txt.gz |
| PGS001874 (portability-PLR_706.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Sebaceous cyst | Epidermal Inclusion Cyst | 563 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001874/ScoringFiles/PGS001874.txt.gz |
| PGS002014 (portability-ldpred2_172) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Skin cancer | skin carcinoma | 534,399 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002014/ScoringFiles/PGS002014.txt.gz |
| PGS002015 (portability-ldpred2_174.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Breast cancer (female) | breast carcinoma | 488,608 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002015/ScoringFiles/PGS002015.txt.gz |
| PGS002081 (portability-ldpred2_681) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Superficial cellulitis and abscess | cellulitis | 640,921 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002081/ScoringFiles/PGS002081.txt.gz |
| PGS002083 (portability-ldpred2_696.4) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Psoriasis | psoriasis | 71,744 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002083/ScoringFiles/PGS002083.txt.gz |
| PGS002084 (portability-ldpred2_697) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Sarcoidosis | skin sarcoidosis | 403,417 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002084/ScoringFiles/PGS002084.txt.gz |
| PGS002085 (portability-ldpred2_702.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Seborrheic keratosis | seborrheic keratosis | 481,233 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002085/ScoringFiles/PGS002085.txt.gz |
| PGS002086 (portability-ldpred2_704) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Diseases of hair and hair follicles | disorder of pilosebaceous unit | 160,693 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002086/ScoringFiles/PGS002086.txt.gz |
| PGS002087 (portability-ldpred2_706.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Sebaceous cyst | Epidermal Inclusion Cyst | 206,669 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002087/ScoringFiles/PGS002087.txt.gz |
| PGS002242 (ldpred_breastcancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Breast cancer | breast carcinoma | 6,494,889 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002242/ScoringFiles/PGS002242.txt.gz | |
| PGS002293 (PRS62_psoriasis) |
PGP000323 | Shen M et al. J Am Acad Dermatol (2022) |
Psoriasis | psoriasis | 62 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002293/ScoringFiles/PGS002293.txt.gz |
| PGS002294 (PRS111) |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Breast cancer | breast carcinoma | 111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002294/ScoringFiles/PGS002294.txt.gz | |
| PGS002320 (disease_DERMATOLOGY.BOLT-LMM) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 1,109,311 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002320/ScoringFiles/PGS002320.txt.gz |
| PGS002344 (disease_PSORIASIS.BOLT-LMM) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 1,109,311 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002344/ScoringFiles/PGS002344.txt.gz |
| PGS002392 (disease_DERMATOLOGY.P+T.0.0001) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 3,539 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002392/ScoringFiles/PGS002392.txt.gz |
| PGS002416 (disease_PSORIASIS.P+T.0.0001) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 6,879 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002416/ScoringFiles/PGS002416.txt.gz |
| PGS002441 (disease_DERMATOLOGY.P+T.0.001) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 14,624 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002441/ScoringFiles/PGS002441.txt.gz |
| PGS002465 (disease_PSORIASIS.P+T.0.001) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 21,483 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002465/ScoringFiles/PGS002465.txt.gz |
| PGS002490 (disease_DERMATOLOGY.P+T.0.01) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 88,324 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002490/ScoringFiles/PGS002490.txt.gz |
| PGS002514 (disease_PSORIASIS.P+T.0.01) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 96,453 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002514/ScoringFiles/PGS002514.txt.gz |
| PGS002539 (disease_DERMATOLOGY.P+T.1e-06) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 540 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002539/ScoringFiles/PGS002539.txt.gz |
| PGS002563 (disease_PSORIASIS.P+T.1e-06) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 1,348 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002563/ScoringFiles/PGS002563.txt.gz |
| PGS002588 (disease_DERMATOLOGY.P+T.5e-08) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 240 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002588/ScoringFiles/PGS002588.txt.gz |
| PGS002612 (disease_PSORIASIS.P+T.5e-08) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 643 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002612/ScoringFiles/PGS002612.txt.gz |
| PGS002637 (disease_DERMATOLOGY.PolyFun-pred) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 164,178 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002637/ScoringFiles/PGS002637.txt.gz |
| PGS002661 (disease_PSORIASIS.PolyFun-pred) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 283,128 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002661/ScoringFiles/PGS002661.txt.gz |
| PGS002686 (disease_DERMATOLOGY.SBayesR) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Dermatologic diseases | skin disease | 815,851 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002686/ScoringFiles/PGS002686.txt.gz |
| PGS002710 (disease_PSORIASIS.SBayesR) |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Psoriasis | psoriasis | 566,839 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002710/ScoringFiles/PGS002710.txt.gz |
| PGS002755 (Atopic_dermatitis_prscs) |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Atopic dermatitis | atopic eczema | 1,090,702 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002755/ScoringFiles/PGS002755.txt.gz |
| PGS003380 (best_BRCA) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Breast cancer | breast carcinoma | 1,142,637 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003380/ScoringFiles/PGS003380.txt.gz |
| PGS003382 (best_SKCM) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Skin cutaneous melanoma | cutaneous melanoma | 672 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003382/ScoringFiles/PGS003382.txt.gz |
| PGS003396 (PRS-11ASN) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003396/ScoringFiles/PGS003396.txt.gz |
| PGS003397 (PRS-42ASN) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 42 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003397/ScoringFiles/PGS003397.txt.gz |
| PGS003398 (PRS-136EUR) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 136 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003398/ScoringFiles/PGS003398.txt.gz |
| PGS003399 (PRS-209EUR) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 209 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003399/ScoringFiles/PGS003399.txt.gz |
| PGS003416 (MTAGPRS) |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Basal cell carcinoma (MTAG) | basal cell carcinoma | 462 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003416/ScoringFiles/PGS003416.txt.gz |
| PGS003417 (UKBPRS) |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Basal cell carcinoma | basal cell carcinoma | 273 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003417/ScoringFiles/PGS003417.txt.gz |
| PGS003459 (PRS_CO) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Atopic eczema or atopic disease | atopic eczema, allergic disease |
170 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003459/ScoringFiles/PGS003459.txt.gz |
| PGS003486 (PRS_AE) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Atopic eczema | atopic eczema | 71 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003486/ScoringFiles/PGS003486.txt.gz |
| PGS003738 (PRS136_BC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Breast cancer | breast carcinoma | 136 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003738/ScoringFiles/PGS003738.txt.gz | |
| PGS003745 (PRS57_SM) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Skin Melanoma | cutaneous melanoma | 57 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003745/ScoringFiles/PGS003745.txt.gz | |
| PGS003758 (BrCa_PRS_JPHC_JPGWAS) |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Breast cancer | breast carcinoma | 46,861 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003758/ScoringFiles/PGS003758.txt.gz | |
| PGS003759 (BrCa_PRS_JPHC_EURGWAS) |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Breast cancer | breast carcinoma | 17,252 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003759/ScoringFiles/PGS003759.txt.gz | |
| PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 1,137,459 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003983/ScoringFiles/PGS003983.txt.gz | |
| PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 13,086 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003999/ScoringFiles/PGS003999.txt.gz | |
| PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 1,041,298 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004025/ScoringFiles/PGS004025.txt.gz | |
| PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 1,041,298 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004040/ScoringFiles/PGS004040.txt.gz | |
| PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 869,407 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004053/ScoringFiles/PGS004053.txt.gz | |
| PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 869,407 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004069/ScoringFiles/PGS004069.txt.gz | |
| PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 1,103,877 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004083/ScoringFiles/PGS004083.txt.gz | |
| PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 209 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004107/ScoringFiles/PGS004107.txt.gz | |
| PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 982 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004123/ScoringFiles/PGS004123.txt.gz | |
| PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 950,524 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004137/ScoringFiles/PGS004137.txt.gz | |
| PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Breast cancer | breast carcinoma | 1,133,268 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004153/ScoringFiles/PGS004153.txt.gz | |
| PGS004166 (bc_1) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 3,920 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004166/ScoringFiles/PGS004166.txt.gz |
| PGS004167 (bc_2) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 717 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004167/ScoringFiles/PGS004167.txt.gz |
| PGS004168 (bc_3) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 4,618 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004168/ScoringFiles/PGS004168.txt.gz |
| PGS004169 (bc_4) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 1,361 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004169/ScoringFiles/PGS004169.txt.gz |
| PGS004170 (bc_5) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 2,278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004170/ScoringFiles/PGS004170.txt.gz |
| PGS004242 (PRS306_breast) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Breast cancer | breast carcinoma | 306 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004242/ScoringFiles/PGS004242.txt.gz |
| PGS004247 (PRS65_melanoma) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Melanoma | cutaneous melanoma | 65 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004247/ScoringFiles/PGS004247.txt.gz |
| PGS004315 (GRS-ALL) |
PGP000547 | Bui A et al. Front Genet (2023) |
Psoriasis | psoriasis | 88 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004315/ScoringFiles/PGS004315.txt.gz |
| PGS004316 (GRS-HLA) |
PGP000547 | Bui A et al. Front Genet (2023) |
Psoriasis | psoriasis | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004316/ScoringFiles/PGS004316.txt.gz |
| PGS004317 (GRS-noHLA) |
PGP000547 | Bui A et al. Front Genet (2023) |
Psoriasis | psoriasis | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004317/ScoringFiles/PGS004317.txt.gz |
| PGS004324 (PRS6314_PN) |
PGP000558 | Vasavda C et al. J Invest Dermatol (2023) |
Prurigo nodularis | prurigo nodularis | 6,314 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004324/ScoringFiles/PGS004324.txt.gz | |
| PGS004441 (disease.breast_cancer.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
Breast cancer | breast carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004441/ScoringFiles/PGS004441.txt.gz |
| PGS004511 (meta.breast_cancer.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
Breast cancer | breast carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004511/ScoringFiles/PGS004511.txt.gz |
| PGS004579 (BRCA_PRSCS) |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Breast cancer | breast carcinoma | 1,088,163 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004579/ScoringFiles/PGS004579.txt.gz |
| PGS004587 (PRS23_AD) |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |
Atopic dermatitis | atopic eczema | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004587/ScoringFiles/PGS004587.txt.gz |
| PGS004592 (PRS_KC) |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Keratinocyte cancer | keratinocyte carcinoma | 78 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004592/ScoringFiles/PGS004592.txt.gz |
| PGS004611 (RORP_PRS) |
PGP000590 | Shieh Y et al. NPJ Precis Oncol (2023) |
Breast cancer | breast carcinoma | 76 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004611/ScoringFiles/PGS004611.txt.gz | |
| PGS004688 (breast_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Breast cancer | breast carcinoma | 1,044,110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004688/ScoringFiles/PGS004688.txt.gz | |
| PGS004737 (breast_cancer_PRSmix_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Breast cancer | breast carcinoma | 3,666,245 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004737/ScoringFiles/PGS004737.txt.gz |
| PGS004738 (breast_cancer_PRSmixPlus_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Breast cancer | breast carcinoma | 3,666,321 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004738/ScoringFiles/PGS004738.txt.gz |
| PGS004865 (PRS105_BC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Breast cancer | breast carcinoma | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004865/ScoringFiles/PGS004865.txt.gz |
| PGS004866 (PRS105_ERposBC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004866/ScoringFiles/PGS004866.txt.gz |
| PGS004867 (PRS105_ERnegBC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004867/ScoringFiles/PGS004867.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000011 | PGS000001 (PRS77_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: Invasive breast cancer | OR: 1.46 [1.42, 1.49] | AUROC: 0.603 | — | study, genetic PCs 1-15 | — |
| PPM000114 | PGS000001 (PRS77_BC) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.13 [1.1, 1.16] | — | — | Country, birth year | — |
| PPM000117 | PGS000001 (PRS77_BC) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.28] | — | — | Country, birth year | — |
| PPM000001 | PGS000001 (PRS77_BC) |
PSS000001| European Ancestry| 67,054 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: All breast cancer | OR: 1.55 [1.52, 1.58] | C-index: 0.622 [0.619, 0.627] | — | — | — |
| PPM000962 | PGS000001 (PRS77_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.21 [1.13, 1.29] | — | — | Country | — |
| PPM000945 | PGS000001 (PRS77_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.21 [1.13, 1.29] | — | — | Country | — |
| PPM000944 | PGS000001 (PRS77_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.21 [1.14, 1.29] | — | — | Country | — |
| PPM000961 | PGS000001 (PRS77_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.21 [1.14, 1.29] | — | — | Country | — |
| PPM002152 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers 40 years of age or below | HR: 1.43 [1.04, 1.97] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002150 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.71 [1.36, 2.15] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002151 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 2.29 [1.56, 3.38] | — | — | Year of birth, counselling center of origin, PRS*c.1100delC carrier status | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002153 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 41 and 50 years of age | HR: 2.32 [1.69, 3.2] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002154 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 51 and 60 years of age | HR: 1.59 [1.07, 2.35] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM017270 | PGS000001 (PRS77_BC) |
PSS010184| European Ancestry| 200,195 individuals |
PGP000455 | Spaeth EL et al. Cancer Prev Res (Phila) (2023) |Ext. |
Reported Trait: breast cancer | HR: 1.38 [1.34, 1.42] | C-index: 0.628 [0.618, 0.638] | — | — | — |
| PPM021128 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | OR: 1.41 [1.25, 1.59] β: 0.3432 (0.0696) |
— | — | — | — |
| PPM021129 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | OR: 1.37 [1.21, 1.55] β: 0.3154 (0.0631) |
— | — | Questionnaire score, percent mammographic density | — |
| PPM021130 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | — | AUROC: 0.658 | — | Age, percent mammographic density, questionnaire score | — |
| PPM021131 | PGS000001 (PRS77_BC) |
PSS011535| Ancestry Not Reported| 1,336 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | — | AUROC: 0.687 | — | Age, mammographic percent density, questionnaire score | — |
| PPM021132 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | — | AUROC: 0.659 | — | Age, BIRADs for mammographic density clasification, questionnaire score | — |
| PPM000012 | PGS000002 (PRS77_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: ER-positive breast cancer | OR: 1.52 [1.48, 1.56] | AUROC: 0.615 | — | study, genetic PCs 1-15 | — |
| PPM000002 | PGS000002 (PRS77_ERpos) |
PSS000003| European Ancestry| 53,923 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: ER-positive breast cancer | OR: 1.63 [1.6, 1.67] | — | — | — | — |
| PPM000115 | PGS000002 (PRS77_ERpos) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.09 [1.06, 1.12] | — | — | Country, birth year | — |
| PPM000118 | PGS000002 (PRS77_ERpos) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.27] | — | — | Country, birth year | — |
| PPM000013 | PGS000003 (PRS77_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: ER-negative breast cancer | OR: 1.35 [1.27, 1.43] | AUROC: 0.584 | — | study, genetic PCs 1-15 | — |
| PPM000116 | PGS000003 (PRS77_ERneg) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.24 [1.21, 1.28] | — | — | Country, birth year | — |
| PPM000119 | PGS000003 (PRS77_ERneg) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.13 [1.08, 1.18] | — | — | Country, birth year | — |
| PPM000003 | PGS000003 (PRS77_ERneg) |
PSS000002| European Ancestry| 38,722 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: ER-negative breast cancer | OR: 1.45 [1.4, 1.49] | — | — | — | — |
| PPM000005 | PGS000004 (PRS313_BC) |
PSS000007| European Ancestry| 190,040 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Incident breast cancer cases | HR: 1.59 [1.54, 1.64] | — | — | study, genetic PCs 1-15 | Included only 306 of the 313 SNPs |
| PPM000004 | PGS000004 (PRS313_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.61 [1.57, 1.65] | AUROC: 0.63 | — | study, genetic PCs 1-15 | — |
| PPM000940 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.39 [1.13, 1.7] | — | — | Age, country, PCs (1-10) | — |
| PPM000938 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.3 [1.26, 1.35] | — | — | Age, country | — |
| PPM001345 | PGS000004 (PRS313_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | HR: 1.55 [1.52, 1.58] | — | — | 10 ancestry PCs, batch, age as time scale | 260/313 variants in the PRS are polymorphic in FinnGen |
| PPM000941 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.67 [1.59, 1.76] | — | — | Age, country, PCs (1-10) | — |
| PPM000957 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.39 [1.13, 1.7] | — | — | Age, country, PCs (1-10) | — |
| PPM000959 | PGS000004 (PRS313_BC) |
PSS000481| Additional Asian Ancestries| 12,473 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.15 [1.02, 1.29] | — | — | Age, country | — |
| PPM000955 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.3 [1.26, 1.35] | — | — | Age, country | — |
| PPM001347 | PGS000004 (PRS313_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | OR: 1.61 [1.57, 1.64] | — | — | Age, 10 ancestry PCs, batch | 260/313 variants in the PRS are polymorphic in FinnGen |
| PPM000958 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.67 [1.59, 1.76] | — | — | Age, country, PCs (1-10) | — |
| PPM000954 | PGS000004 (PRS313_BC) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.38 [1.23, 1.55] | — | — | Country | — |
| PPM000953 | PGS000004 (PRS313_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.32] | — | — | Country | — |
| PPM000951 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.18, 1.33] | C-index: 0.563 [0.547, 0.586] | — | Country | — |
| PPM000942 | PGS000004 (PRS313_BC) |
PSS000481| Additional Asian Ancestries| 12,473 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.15 [1.02, 1.29] | — | — | Age, country | — |
| PPM000960 | PGS000004 (PRS313_BC) |
PSS000480| Additional Asian Ancestries| 25,531 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.56 [1.52, 1.6] | — | — | Age, country | — |
| PPM000956 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.82 [1.8, 1.84] | — | — | Age, country | — |
| PPM000943 | PGS000004 (PRS313_BC) |
PSS000480| Additional Asian Ancestries| 25,531 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.56 [1.52, 1.6] | — | — | Age, country | — |
| PPM000937 | PGS000004 (PRS313_BC) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.38 [1.23, 1.55] | — | — | Country | — |
| PPM000936 | PGS000004 (PRS313_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.32] | — | — | Country | — |
| PPM000935 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | — | C-index: 0.623 [0.591, 0.629] | — | Country, age at first diagnosis, year of first diagnosis, family history for breast cancer in a first degree relative, clinical characteristics of the first breast cancer (nodal status, tumor size, differentiation grade, morphology, estrogen receptor status, human epidermal growth factor receptor 2 status, chemotherapy, endocrine therapy, radiotherapy) | — |
| PPM000934 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.18, 1.33] | C-index: 0.563 [0.547, 0.586] | — | Country | — |
| PPM000952 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | — | C-index: 0.623 [0.591, 0.629] | — | Country, age at first diagnosis, year of first diagnosis, family history for breast cancer in a first degree relative, clinical characteristics of the first breast cancer (nodal status, tumor size, differentiation grade, morphology, estrogen receptor status, human epidermal growth factor receptor 2 status, chemotherapy, endocrine therapy, radiotherapy) | — |
| PPM000939 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.82 [1.8, 1.84] | — | — | Age, country | — |
| PPM001012 | PGS000004 (PRS313_BC) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.2 [1.17, 1.23] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001013 | PGS000004 (PRS313_BC) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.31 [1.26, 1.36] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001014 | PGS000004 (PRS313_BC) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.09 [1.05, 1.13] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001015 | PGS000004 (PRS313_BC) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.19 [1.1, 1.29] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001016 | PGS000004 (PRS313_BC) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.44 [1.35, 1.54] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001017 | PGS000004 (PRS313_BC) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.36 [1.3, 1.43] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001035 | PGS000004 (PRS313_BC) |
PSS000531| European Ancestry| 1,757 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Incidient breast cancer in BRCA2 carriers | HR: 1.36 [1.17, 1.57] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
| PPM000662 | PGS000004 (PRS313_BC) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.38 [1.31, 1.44] | AUROC: 0.5877 | — | — | — |
| PPM000659 | PGS000004 (PRS313_BC) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.49 [1.38, 1.6] | AUROC: 0.6093 | — | — | — |
| PPM000656 | PGS000004 (PRS313_BC) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.68 [1.6, 1.77] | AUROC: 0.6432 | — | — | — |
| PPM000653 | PGS000004 (PRS313_BC) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.55, 1.71] | AUROC: 0.6336 | — | — | — |
| PPM000650 | PGS000004 (PRS313_BC) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.8 [1.75, 1.86] | AUROC: 0.6573 | — | — | — |
| PPM001646 | PGS000004 (PRS313_BC) |
PSS000854| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.628 [0.62, 0.637] | — | Genotyping array | Missing 25 variants (8%) based on availability of variants in the cohort |
| PPM001647 | PGS000004 (PRS313_BC) |
PSS000854| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.633 [0.624, 0.641] | — | family history of cancer (in first-degree relatives), genotyping array | Missing 25 variants (8%) based on availability of variants in the cohort |
| PPM001945 | PGS000004 (PRS313_BC) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.55 [1.45, 1.66] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.86 [3.07, 4.87] | — | — |
| PPM001946 | PGS000004 (PRS313_BC) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.51 [1.42, 1.61] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.38 [2.74, 4.18] | — | — |
| PPM001958 | PGS000004 (PRS313_BC) |
PSS000979| Multi-ancestry (including European)| 19,264 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer in carriers of a hereditary breast and ovarian cancer variant | OR: 1.44 [1.19, 1.74] | — | Odds Ratio (OR, top 20% vs bottom 20%): 3.04 [1.61, 5.73] | Age, PCs (1-4) | — |
| PPM001959 | PGS000004 (PRS313_BC) |
PSS000979| Multi-ancestry (including European)| 19,264 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer in non-carriers of a hereditary breast and ovarian cancer variant | OR: 1.57 [1.49, 1.65] | — | — | Age, PCs (1-4) | — |
| PPM001960 | PGS000004 (PRS313_BC) |
PSS000980| Multi-ancestry (including European)| 26,595 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Prevalent breast cancer | OR: 1.61 [1.52, 1.7] | — | — | Age, PCs (1-4) | — |
| PPM001999 | PGS000004 (PRS313_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.27 [1.23, 1.31] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.54 [1.38, 1.72] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM002000 | PGS000004 (PRS313_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.571 [0.562, 0.579] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM005171 | PGS000004 (PRS313_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.51, 0.58] | R²: 0.0003 | — | — |
| PPM005118 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.4 [1.06, 1.85] | — | — | PCs(1-3) | — |
| PPM005168 | PGS000004 (PRS313_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.59, 0.61] | R²: 0.025 | — | — |
| PPM005148 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Incident invasive estrogen receptor postivie/progesterone receptor positive breast cancer | HR: 1.53 [1.22, 1.91] | — | — | Family history of breast cancer (first-degree blood relatives), treatment (asprin/placebo), age at enrolment, number of children, alcohol use, body mass index at enrolment, use of hormone replacement therapy at enrolment | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005150 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Diagnosis of prevalent invasive breast cancer before the age of 50 | OR: 1.39 [1.08, 1.8] | — | — | Family history of breast cancer (first-degree blood relatives) | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005151 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Diagnosis of prevalent invasive breast cancer at the age of 50 or over | OR: 1.47 [1.33, 1.63] | — | — | Family history of breast cancer (first-degree blood relatives) | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005159 | PGS000004 (PRS313_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.4 [1.35, 1.45] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005162 | PGS000004 (PRS313_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.26 [1.1, 1.44] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005165 | PGS000004 (PRS313_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.3 [1.08, 1.57] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005174 | PGS000004 (PRS313_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.5, 0.6] | R²: 0.0008 | — | — |
| PPM005119 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.39 [1.05, 1.84] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005120 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.44 [1.07, 1.95] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM005121 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.32 [1.15, 1.52] | — | — | PCs(1-3) | — |
| PPM005122 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.33 [1.15, 1.52] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005123 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.36 [1.18, 1.57] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM005147 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Incident invasive breast cancer | HR: 1.43 [1.18, 1.73] | C-index: 0.65 [0.59, 0.71] | Hazard Ratio (HR, top 20% vs bottom 20%): 2.16 [1.21, 3.86] | Family history of breast cancer (first-degree blood relatives), treatment (asprin/placebo), age at enrolment, number of children, alcohol use, body mass index at enrolment, use of hormone replacement therapy at enrolment | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005149 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Prevalent invasive breast cancer | OR: 1.47 [1.34, 1.61] | AUROC: 0.62 [0.59, 0.65] | Odds Ratio (OR, top 20% vs bottom 20%): 3.16 [2.26, 4.49] | Family history of breast cancer (first-degree blood relatives), pathogenic variants in breast cancer-associated genes | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM012885 | PGS000004 (PRS313_BC) |
PSS009592| Ancestry Not Reported| 5,023 individuals |
PGP000292 | Saad M et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Breast cancer | OR: 1.432 [1.333, 1.538] | AUROC: 0.6 [0.581, 0.62] | — | — | — |
| PPM012909 | PGS000004 (PRS313_BC) |
PSS009609| European Ancestry| 54,949 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.631 [0.61, 0.651] | Calibration (E/O): 0.9 [0.7, 1.0] | — | — |
| PPM012910 | PGS000004 (PRS313_BC) |
PSS009610| European Ancestry| 238,663 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.622 [0.614, 0.63] | Calibration (E/O): 1.0 [0.7, 1.3] | — | — |
| PPM012912 | PGS000004 (PRS313_BC) |
PSS009610| European Ancestry| 238,663 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.64 [0.632, 0.647] | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012913 | PGS000004 (PRS313_BC) |
PSS009611| European Ancestry| 302,425 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.668 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012914 | PGS000004 (PRS313_BC) |
PSS009612| European Ancestry| 840,867 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.664 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012915 | PGS000004 (PRS313_BC) |
PSS009613| European Ancestry| 408,679 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.666 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012916 | PGS000004 (PRS313_BC) |
PSS009614| European Ancestry| 188,453 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.661 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012917 | PGS000004 (PRS313_BC) |
PSS009615| European Ancestry| 1,401,091 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.664 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012918 | PGS000004 (PRS313_BC) |
PSS009616| European Ancestry| 5,328,392 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.665 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012911 | PGS000004 (PRS313_BC) |
PSS009609| European Ancestry| 54,949 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.64 [0.62, 0.66] | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM014886 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.061 [0.017, 0.105] | — | — | first 10 principal components | — |
| PPM014887 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.06 [0.016, 0.104] | — | — | first 10 principal components | — |
| PPM014888 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.081 [0.037, 0.125] | — | — | first 10 principal components | — |
| PPM014889 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.058 [0.016, 0.101] | — | — | first 10 principal components | — |
| PPM015579 | PGS000004 (PRS313_BC) |
PSS009990| Multi-ancestry (including European)| 207,510 individuals |
PGP000389 | Giardiello D et al. Breast Cancer Res (2022) |Ext. |
Reported Trait: Contralateral breast cancer | — | — | Subdistributional hazard ratio (sHR, 75th vs. 25th quartile): 1.35 [1.31, 1.39] | PredictCBC-2.0A | Calculated with PredictCBC-2.0A |
| PPM017271 | PGS000004 (PRS313_BC) |
PSS010184| European Ancestry| 200,195 individuals |
PGP000455 | Spaeth EL et al. Cancer Prev Res (Phila) (2023) |Ext. |
Reported Trait: breast cancer | HR: 1.45 [1.4, 1.49] | C-index: 0.567 [0.556, 0.577] | — | — | — |
| PPM018546 | PGS000004 (PRS313_BC) |
PSS011015| East Asian Ancestry| 8,001 individuals |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |Ext. |
Reported Trait: Incident breast cancer | — | C-index: 0.582 (0.018) | Improvement in C-index from age-only model: 0.042 Hazard ratio (HR, high vs low tertile): 1.89 [1.25, 2.86] |
age | — |
| PPM020279 | PGS000004 (PRS313_BC) |
PSS011321| African Ancestry| 10,717 individuals |
PGP000537 | Luoh SW et al. Health Equity (2023) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.579 [0.522, 0.636] | — | — | — |
| PPM020280 | PGS000004 (PRS313_BC) |
PSS011322| European Ancestry| 19,939 individuals |
PGP000537 | Luoh SW et al. Health Equity (2023) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.622 [0.58, 0.664] | — | — | — |
| PPM020422 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in women aged 40-54 years at study enrolment | HR: 1.68 [1.52, 1.84] | — | — | Age, genotyping method | — |
| PPM020423 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in women aged 55-74 years at study enrolment | HR: 1.53 [1.42, 1.65] | — | — | Age, genotyping method | — |
| PPM020424 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in full sisters of women aged 40-54 years at study enrolment | HR: 1.27 [1.04, 1.55] | — | — | Age, genotyping method | — |
| PPM020425 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in full sisters of women aged 55-74 years at study enrolment | HR: 1.24 [1.07, 1.44] | — | — | Age, genotyping method | — |
| PPM020724 | PGS000004 (PRS313_BC) |
PSS011385| European Ancestry| 683 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Grade 3 tumour in females with invasive breast cancer | OR: 0.8 [0.65, 0.99] | — | — | — | Reference = grade 1 tumour |
| PPM020725 | PGS000004 (PRS313_BC) |
PSS011385| European Ancestry| 683 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: ER negative status in females with invasive breast cancer | OR: 0.8 [0.65, 0.99] | — | — | — | — |
| PPM020726 | PGS000004 (PRS313_BC) |
PSS011384| Additional Asian Ancestries| 12,920 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: ER negative status in females with invasive breast cancer | OR: 0.86 [0.82, 0.89] | — | — | — | — |
| PPM020727 | PGS000004 (PRS313_BC) |
PSS011385| European Ancestry| 683 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: PR negative status in females with invasive breast cancer | OR: 0.84 [0.71, 1.0] | — | — | — | — |
| PPM020728 | PGS000004 (PRS313_BC) |
PSS011384| Additional Asian Ancestries| 12,920 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: PR negative status in females with invasive breast cancer | OR: 0.89 [0.86, 0.94] | — | — | — | — |
| PPM000006 | PGS000005 (PRS313_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-positive breast cancer | OR: 1.68 [1.63, 1.73] | AUROC: 0.641 | — | study, genetic PCs 1-15 | — |
| PPM000964 | PGS000005 (PRS313_ERpos) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.22 [1.15, 1.3] | — | — | Country | — |
| PPM000963 | PGS000005 (PRS313_ERpos) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.23 [1.16, 1.31] | — | — | Country | — |
| PPM000947 | PGS000005 (PRS313_ERpos) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.22 [1.15, 1.3] | — | — | Country | — |
| PPM000946 | PGS000005 (PRS313_ERpos) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.23 [1.16, 1.31] | — | — | Country | — |
| PPM000965 | PGS000005 (PRS313_ERpos) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.37 [1.22, 1.54] | — | — | Country | — |
| PPM000948 | PGS000005 (PRS313_ERpos) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.37 [1.22, 1.54] | — | — | Country | — |
| PPM001018 | PGS000005 (PRS313_ERpos) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.17 [1.14, 1.2] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001019 | PGS000005 (PRS313_ERpos) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.3 [1.26, 1.35] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001020 | PGS000005 (PRS313_ERpos) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.06 [1.02, 1.1] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001021 | PGS000005 (PRS313_ERpos) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.15 [1.07, 1.25] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001022 | PGS000005 (PRS313_ERpos) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.45 [1.35, 1.54] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001023 | PGS000005 (PRS313_ERpos) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.37 [1.31, 1.44] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM000654 | PGS000005 (PRS313_ERpos) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.54, 1.7] | AUROC: 0.6323 | — | — | — |
| PPM000663 | PGS000005 (PRS313_ERpos) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.59 [1.51, 1.66] | AUROC: 0.6276 | — | — | — |
| PPM000660 | PGS000005 (PRS313_ERpos) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.59 [1.48, 1.71] | AUROC: 0.6291 | — | — | — |
| PPM000657 | PGS000005 (PRS313_ERpos) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.66 [1.58, 1.75] | AUROC: 0.64 | — | — | — |
| PPM000651 | PGS000005 (PRS313_ERpos) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.82 [1.77, 1.87] | AUROC: 0.6595 | — | — | — |
| PPM001947 | PGS000005 (PRS313_ERpos) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.55 [1.45, 1.66] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 4.01 [3.17, 5.06] | — | — |
| PPM001948 | PGS000005 (PRS313_ERpos) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.5 [1.41, 1.6] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.26 [2.64, 4.03] | — | — |
| PPM002001 | PGS000005 (PRS313_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.37 [1.32, 1.43] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.85 [1.61, 2.13] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM002002 | PGS000005 (PRS313_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.588 [0.577, 0.599] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM005127 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.4 [1.07, 1.83] | AUROC: 0.6 [0.51, 0.69] | — | PCs(1-3) | — |
| PPM005128 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.39 [1.06, 1.82] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005129 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.46 [1.09, 1.94] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM005130 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.33 [1.16, 1.52] | AUROC: 0.59 [0.55, 0.63] | — | PCs(1-3) | — |
| PPM005131 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.33 [1.16, 1.53] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005132 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.36 [1.18, 1.57] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM014895 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.056 [0.012, 0.1] | — | — | first 10 principal components | — |
| PPM014896 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.055 [0.011, 0.099] | — | — | first 10 principal components | — |
| PPM014897 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.078 [0.034, 0.121] | — | — | first 10 principal components | — |
| PPM014898 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.056 [0.014, 0.099] | — | — | first 10 principal components | — |
| PPM000007 | PGS000006 (PRS313_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-negative breast cancer | OR: 1.45 [1.37, 1.53] | AUROC: 0.601 | — | study, genetic PCs 1-15 | — |
| PPM000950 | PGS000006 (PRS313_ERneg) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.33] | — | — | Country | — |
| PPM000949 | PGS000006 (PRS313_ERneg) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.17, 1.33] | — | — | Country | — |
| PPM000967 | PGS000006 (PRS313_ERneg) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.33] | — | — | Country | — |
| PPM000966 | PGS000006 (PRS313_ERneg) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.17, 1.33] | — | — | Country | — |
| PPM001024 | PGS000006 (PRS313_ERneg) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.29 [1.25, 1.33] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001025 | PGS000006 (PRS313_ERneg) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.23 [1.18, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001026 | PGS000006 (PRS313_ERneg) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.23 [1.18, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001027 | PGS000006 (PRS313_ERneg) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.29 [1.19, 1.41] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001028 | PGS000006 (PRS313_ERneg) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.29 [1.21, 1.37] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001029 | PGS000006 (PRS313_ERneg) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.21 [1.15, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001034 | PGS000006 (PRS313_ERneg) |
PSS000529| European Ancestry| 2,088 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in BRCA1 carriers | HR: 1.28 [1.14, 1.44] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
| PPM001949 | PGS000006 (PRS313_ERneg) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.37 [1.29, 1.47] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 2.39 [1.93, 2.96] | — | — |
| PPM001950 | PGS000006 (PRS313_ERneg) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.38 [1.29, 1.47] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 2.51 [2.05, 3.07] | — | — |
| PPM002003 | PGS000006 (PRS313_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor negative breast cancer | OR: 1.21 [1.15, 1.27] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.47 [1.25, 1.74] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM002004 | PGS000006 (PRS313_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor negative breast cancer | — | AUROC: 0.562 [0.551, 0.573] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM005124 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.23 [1.07, 1.41] | — | — | PCs(1-3) | — |
| PPM005125 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.23 [1.07, 1.42] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005126 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.25 [1.09, 1.45] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM014890 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.059 [0.015, 0.103] | — | — | first 10 principal components | — |
| PPM014892 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.068 [0.024, 0.112] | — | — | first 10 principal components | — |
| PPM014893 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.046 [0.003, 0.089] | — | — | first 10 principal components | — |
| PPM014894 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus-white Mammogram Risk Scores | β: 0.045 [0.002, 0.089] | — | — | first 10 principal components | — |
| PPM014891 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.065 [0.021, 0.109] | — | — | first 10 principal components | — |
| PPM000008 | PGS000007 (PRS3820_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.66 [1.61, 1.7] | AUROC: 0.636 | — | study, genetic PCs 1-15 | — |
| PPM000386 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.78 | — | age, sex | — |
| PPM000384 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | OR: 1.56 [1.45, 1.68] | — | — | age at menarche | — |
| PPM000388 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.63 | — | — | — |
| PPM005169 | PGS000007 (PRS3820_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.59 [0.58, 0.6] | R²: 0.021 | — | — |
| PPM005172 | PGS000007 (PRS3820_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.53 [0.5, 0.57] | R²: 0.0002 | — | — |
| PPM005160 | PGS000007 (PRS3820_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.36 [1.31, 1.41] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005163 | PGS000007 (PRS3820_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.21 [1.06, 1.39] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM015517 | PGS000007 (PRS3820_BC) |
PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Breast cancer | OR: 2.38 [2.07, 2.73] | — | — | 4 genetic PCs | — |
| PPM000009 | PGS000008 (PRS3820_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-positive breast cancer | OR: 1.73 [1.68, 1.78] | AUROC: 0.647 | — | study, genetic PCs 1-15 | — |
| PPM000010 | PGS000009 (PRS3820_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-negative breast cancer | OR: 1.44 [1.36, 1.53] | AUROC: 0.6 | — | study, genetic PCs 1-15 | — |
| PPM000024 | PGS000015 (GPS_BC) |
PSS000014| European Ancestry| 157,895 individuals |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Reported Trait: Breast cancer | — | AUROC: 0.69 [0.68, 0.69] | Nagelkerke’s R2 (estimate of variance explained by the PGS after covariate adjustment): 0.027 | age; sex; Ancestry PC 1-4; genotyping chip | — |
| PPM005170 | PGS000015 (GPS_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.61 [0.6, 0.62] | R²: 0.017 | — | — |
| PPM005161 | PGS000015 (GPS_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.46 [1.41, 1.51] | — | Odds Ratio (OR, top 1% vs middle 20%): 2.48 [1.89, 3.25] | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005164 | PGS000015 (GPS_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.24 [1.08, 1.43] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005166 | PGS000015 (GPS_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.35 [1.11, 1.64] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005173 | PGS000015 (GPS_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.52, 0.59] | R²: 0.0004 | — | — |
| PPM005175 | PGS000015 (GPS_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.56 [0.51, 0.6] | R²: 0.001 | — | — |
| PPM000056 | PGS000028 (PRS) |
PSS000040| Multi-ancestry (including European)| 981 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.65 [0.61, 0.68] | — | BCSC risk model | BCSC risk model includes mammographic breast density, age, ethnicity, first-degree relative with breast cancer, and history of breast biopsy |
| PPM000055 | PGS000028 (PRS) |
PSS000040| Multi-ancestry (including European)| 981 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.57, 0.64] | — | — | — |
| PPM000060 | PGS000028 (PRS) |
PSS000039| European Ancestry| 774 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.63 [0.59, 0.67] | — | — | — |
| PPM000059 | PGS000028 (PRS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.62 [0.52, 0.73] | — | — | — |
| PPM000058 | PGS000029 (PRS_AS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.72 [0.62, 0.82] | — | BCSC risk model | BCSC risk model includes mammographic breast density, age, ethnicity, first-degree relative with breast cancer, and history of breast biopsy |
| PPM000057 | PGS000029 (PRS_AS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.64 [0.53, 0.74] | — | — | — |
| PPM000120 | PGS000045 (BCPRS_Overall) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.36 [1.19, 1.56] | AUROC: 0.59 [0.55, 0.63] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
| PPM000106 | PGS000045 (BCPRS_Overall) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.14 [1.11, 1.17] | C-index: 0.541 [0.53, 0.551] | — | Country, birth year | — |
| PPM000107 | PGS000045 (BCPRS_Overall) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.28] | C-index: 0.566 [0.551, 0.581] | — | Country, birth year | — |
| PPM002156 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.9 [1.32, 2.75] | — | — | Year of birth, counselling center of origin, PRS*c.1100delC carrier status | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002155 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.71 [1.37, 2.13] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002157 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers 40 years of age or below | HR: 1.59 [1.2, 2.11] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002158 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 41 and 50 years of age | HR: 2.07 [1.53, 2.82] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002159 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 51 and 60 years of age | HR: 1.56 [1.05, 2.31] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM014912 | PGS000045 (BCPRS_Overall) |
PSS009925| Ancestry Not Reported| 295 individuals |
PGP000355 | Borde J et al. BMC Cancer (2022) |Ext. |
Reported Trait: Breast cancer in BRAC1 PV carriers | OR: 1.62 [1.16, 2.31] | — | — | — | effective SNP set size of N=77 |
| PPM000121 | PGS000046 (BCPRS_ER+) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.36 [1.19, 1.56] | AUROC: 0.59 [0.55, 0.63] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
| PPM000108 | PGS000046 (BCPRS_ER+) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.11 [1.08, 1.15] | C-index: 0.532 [0.522, 0.543] | — | Country, birth year | — |
| PPM000109 | PGS000046 (BCPRS_ER+) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.16, 1.27] | C-index: 0.566 [0.551, 0.581] | — | Country, birth year | — |
| PPM000122 | PGS000047 (BCPRS_ER-) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.19 [1.05, 1.35] | AUROC: 0.55 [0.51, 0.59] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
| PPM000110 | PGS000047 (BCPRS_ER-) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.27 [1.23, 1.31] | C-index: 0.581 [0.571, 0.592] | — | Country, birth year | — |
| PPM000111 | PGS000047 (BCPRS_ER-) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.15 [1.1, 1.2] | C-index: 0.538 [0.523, 0.553] | — | Country, birth year | — |
| PPM014913 | PGS000047 (BCPRS_ER-) |
PSS009925| Ancestry Not Reported| 295 individuals |
PGP000355 | Borde J et al. BMC Cancer (2022) |Ext. |
Reported Trait: Estrogen receptor [ER]-negative breast cancer in BRAC2 PV carriers | OR: 2.27 [1.45, 3.78] | — | — | — | effective SNP set size of N=50 |
| PPM000126 | PGS000050 (PRS44) |
PSS000078| East Asian Ancestry| 23,567 individuals |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.606 | Odds Ratio (OR; per decile of PRS): 1.13 [1.12, 1.14] | NR | Potentially overfit: samples were used to select the variants included in the PRS (see paper's Discussion section for more information). |
| PPM000127 | PGS000050 (PRS44) |
PSS000079| East Asian Ancestry| 5,152 individuals |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Reported Trait: Breast cancer | — | C-index: 0.602 | C-index improvement (with PRS): 0.0386 [0.0259, 0.0513] | age at menarche, age at first live birth, waist-to-hip ratio, breast cancer family history, prior benign breast disease | Potentially overfit: samples were used to select the variants included in the PRS (see paper's Discussion section for more information). |
| PPM000128 | PGS000051 (PRS67) |
PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.65 [0.64, 0.66] | — | Gail BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
| PPM000130 | PGS000051 (PRS67) |
PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | — | Relative Risk (RR; higest vs. lowest quartile PRS): 2.5 [2.2, 2.8] | Demographics and parameters of baseline blood draw (age, BMI, fasting status, time of day, season), history of benign breast disease, family history of breast cancer, age at menopause, age at menarche, physical activity, age at first birth and parity | — |
| PPM000129 | PGS000051 (PRS67) |
PSS000081| Multi-ancestry (including European)| 8,160 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.678 [0.666, 0.69] | — | Rosner-Colditz BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
| PPM000131 | PGS000052 (sPRS161) |
PSS000082| European Ancestry| 585 individuals |
PGP000037 | Lakeman IMM et al. J Med Genet (2019) |
Reported Trait: breast cancer | HR: 1.16 [1.03, 1.28] | — | — | family history (estimated using the BOADICEA risk model) | — |
| PPM000192 | PGS000072 (CC_Breast) |
PSS000111| European Ancestry| 237,549 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Breast cancer | OR: 1.26 [1.24, 1.28] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002038 | PGS000072 (CC_Breast) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident breast cancer | HR: 1.52 [1.47, 1.56] | AUROC: 0.637 C-index: 632.0 (0.005) |
— | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity( ≥1 live birth vs. none), age at menarche, body mass index, menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use, alcool intake, body mass index*menopausal status | Only 162 of the original 187 SNPs used based on those that reached p<5e-8 in the BCAC meta-analysis. C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017165 | PGS000072 (CC_Breast) |
PSS010142| European Ancestry| 1,990 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Post-menopausal breast cancer | HR: 1.26 [1.2, 1.32] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000344 | PGS000119 (BCC32) |
PSS000207| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.32 [1.27, 1.36] | AUROC: 0.58 [0.56, 0.58] | — | age, sex, batch, PC1-4 | — |
| PPM000341 | PGS000119 (BCC32) |
PSS000209| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Basal cell carcinoma | OR: 1.65 [1.56, 1.75] | AUROC: 0.64 [0.62, 0.66] | — | age, sex, batch, PC1-4 | — |
| PPM000347 | PGS000119 (BCC32) |
PSS000211| European Ancestry| 149,857 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.4 [1.42, 1.48] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
| PPM000484 | PGS000153 (cGRS_Breast) |
PSS000273| European Ancestry| 7,847 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.47 [1.23, 1.76] | — | — |
| PPM000473 | PGS000153 (cGRS_Breast) |
PSS000273| European Ancestry| 7,847 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Breast cancer | — | — | Mean realative risk: 1.15 [1.11, 1.2] Wilcoxon test (case vs. control) p-value: 1.48e-14 |
— | — |
| PPM000649 | PGS000212 (PRS330_LumA) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.83 [1.78, 1.88] | AUROC: 0.6609 | — | — | — |
| PPM000652 | PGS000213 (PRS330_LumBHER2neg) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.54, 1.7] | AUROC: 0.633 | — | — | — |
| PPM000655 | PGS000214 (PRS330_LumB) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.69 [1.61, 1.77] | AUROC: 0.6431 | — | — | — |
| PPM000658 | PGS000215 (PRS330_HER2) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.53 [1.42, 1.65] | AUROC: 0.6208 | — | — | — |
| PPM000661 | PGS000216 (PRS330_TN) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.65 [1.57, 1.73] | AUROC: 0.6358 | — | — | — |
| PPM000849 | PGS000317 (PRS180) |
PSS000407| Hispanic or Latin American Ancestry| 2,001 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer (Latin american women) | OR: 1.54 [1.45, 1.63] | AUROC: 0.62 [0.61, 0.64] | — | study, genetic ancestry (ADMIXTURE) | — |
| PPM000848 | PGS000317 (PRS180) |
PSS000408| Hispanic or Latin American Ancestry| 7,317 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer (US Latinas) | OR: 1.62 [1.52, 1.71] | AUROC: 0.63 [0.62, 0.65] | — | study, genetic ancestry (ADMIXTURE) | — |
| PPM000846 | PGS000317 (PRS180) |
PSS000406| Hispanic or Latin American Ancestry| 12,280 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer | OR: 1.58 [1.52, 1.64] | AUROC: 0.63 [0.62, 0.64] | — | study, genetic ancestry (ADMIXTURE) | — |
| PPM000847 | PGS000317 (PRS180) |
PSS000406| Hispanic or Latin American Ancestry| 12,280 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer | OR: 1.7 [1.63, 1.78] | — | — | — | — |
| PPM005167 | PGS000317 (PRS180) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.2 [1.0, 1.46] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005176 | PGS000317 (PRS180) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.54 [0.47, 0.62] | R²: 0.05 | — | — |
| PPM000899 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.75 | — | age, family history of breast cancer, current smoking, BMI, alcohol use disorder, years of hormone replacement therapy, having given birth to one or more children, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM000894 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.737 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM001346 | PGS000332 (PRS_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | HR: 1.63 [1.6, 1.67] | — | — | 10 ancestry PCs, batch, age as time scale | — |
| PPM001348 | PGS000332 (PRS_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | OR: 1.71 [1.67, 1.75] | — | — | Age, 10 ancestry PCs, batch | — |
| PPM000889 | PGS000332 (PRS_BC) |
PSS000443| European Ancestry| 76,173 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Breast cancer (incident and prevalent cases) | HR: 1.64 [1.6, 1.69] | — | — | genotyping array/batch, 10 ancestry PCs | — |
| PPM000903 | PGS000335 (BC_PRSCS) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.8 [1.76, 1.84] | — | — | Age, 10 ancestry PCs, batch | — |
| PPM000902 | PGS000335 (BC_PRSCS) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |
Reported Trait: Breast cancer | HR: 1.71 [1.68, 1.75] | — | — | 10 ancestry PCs, batch, age as time scale | — |
| PPM000922 | PGS000339 (PRS22_CM) |
PSS000464| European Ancestry| 1,885 individuals |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; unaffected melanoma family members vs. unrelated controls): 0.347 (0.104) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
| PPM000921 | PGS000339 (PRS22_CM) |
PSS000463| European Ancestry| 3,066 individuals |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; melanoma family cases vs. unrelated controls): 0.505 (0.036) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
| PPM000970 | PGS000341 (GRS33_SSc) |
PSS000489| European Ancestry| 339 individuals |
PGP000110 | Bossini-Castillo L et al. Ann Rheum Dis (2020) |
Reported Trait: Systemic sclerosis | — | AUROC: 0.787 [0.73, 0.84] | — | Systemic sclerosis status, age and immune cell counts of: memory B cells, resting NK cells, M0 macrophages and activated dendritic cells | *Some overlap with score development and testing samples |
| PPM000969 | PGS000341 (GRS33_SSc) |
PSS000489| European Ancestry| 339 individuals |
PGP000110 | Bossini-Castillo L et al. Ann Rheum Dis (2020) |
Reported Trait: Systemic sclerosis | — | AUROC: 0.722 | — | Systemic sclerosis status and immune cell counts of: memory B cells, resting NK cells, M0 macrophages and activated dendritic cells | *Some overlap with score development and testing samples |
| PPM000968 | PGS000341 (GRS33_SSc) |
PSS000489| European Ancestry| 339 individuals |
PGP000110 | Bossini-Castillo L et al. Ann Rheum Dis (2020) |
Reported Trait: Systemic sclerosis | — | AUROC: 0.644 | — | — | *Some overlap with score development and testing samples |
| PPM000979 | PGS000344 (PRS287_BC) |
PSS000497| Additional Asian Ancestries| 2,719 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.36 [1.25, 1.49] | AUROC: 0.577 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000976 | PGS000344 (PRS287_BC) |
PSS000494| Multi-ancestry (excluding European)| 14,406 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.55 [1.5, 1.61] | — | — | PCs (1-10), study, array,batch | — |
| PPM000973 | PGS000344 (PRS287_BC) |
PSS000491| Additional Asian Ancestries| 32,238 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.52 [1.49, 1.56] | AUROC: 0.613 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000983 | PGS000345 (PRS229_BC) |
PSS000491| Additional Asian Ancestries| 32,238 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.49 [1.45, 1.52] | AUROC: 0.611 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000982 | PGS000345 (PRS229_BC) |
PSS000500| East Asian Ancestry| 10,255 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | HR: 1.49 [1.33, 1.67] | C-index: 0.61 | — | PCs (1-7), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000984 | PGS000345 (PRS229_BC) |
PSS000497| Additional Asian Ancestries| 2,719 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.33 [1.22, 1.45] | AUROC: 0.579 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000981 | PGS000346 (PRS287_ERneg) |
PSS000498| Additional Asian Ancestries| 1,492 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.49 [1.26, 1.75] | AUROC: 0.587 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000978 | PGS000346 (PRS287_ERneg) |
PSS000495| Multi-ancestry (excluding European)| 9,391 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.43 [1.35, 1.52] | — | — | PCs (1-10), study, array,batch | — |
| PPM000975 | PGS000346 (PRS287_ERneg) |
PSS000493| Additional Asian Ancestries| 21,247 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.41 [1.36, 1.46] | AUROC: 0.594 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000980 | PGS000347 (PRS287_ERpos) |
PSS000499| Additional Asian Ancestries| 2,234 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.38 [1.25, 1.53] | AUROC: 0.586 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000977 | PGS000347 (PRS287_ERpos) |
PSS000496| Multi-ancestry (excluding European)| 12,222 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.59 [1.53, 1.66] | — | — | PCs (1-10), study, array,batch | — |
| PPM000974 | PGS000347 (PRS287_ERpos) |
PSS000492| Additional Asian Ancestries| 26,960 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.62 [1.57, 1.67] | AUROC: 0.627 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM001083 | PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.042 [1.003, 1.082] β: 0.0407 (0.0195) |
AUROC: 0.51 [0.499, 0.521] | Nagelkerke's Pseudo-R²: 0.00028 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.7 [1.22, 2.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608 |
| PPM001084 | PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.158 [1.116, 1.202] β: 0.147 (0.0189) |
AUROC: 0.513 [0.503, 0.523] | Nagelkerke's Pseudo-R²: 0.00545 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.56 [1.12, 2.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608 |
| PPM001085 | PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.395] β: 0.294 (0.0197) |
AUROC: 0.581 [0.57, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.63, 2.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608 |
| PPM001086 | PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.396] β: 0.294 (0.0199) |
AUROC: 0.581 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.67, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608 |
| PPM001087 | PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.366 [1.314, 1.421] β: 0.312 (0.0198) |
AUROC: 0.586 [0.576, 0.597] | Nagelkerke's Pseudo-R²: 0.0224 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.23 [1.64, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608 |
| PPM001088 | PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.359 [1.307, 1.413] β: 0.307 (0.0199) |
AUROC: 0.584 [0.573, 0.594] | Nagelkerke's Pseudo-R²: 0.0219 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.2, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608 |
| PPM001089 | PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.369 [1.317, 1.422] β: 0.314 (0.0196) |
AUROC: 0.584 [0.574, 0.594] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.3 [1.72, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608 |
| PPM001090 | PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.338 [1.287, 1.391] β: 0.291 (0.0199) |
AUROC: 0.58 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0192 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.81, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608 |
| PPM001091 | PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.392 [1.339, 1.447] β: 0.331 (0.0199) |
AUROC: 0.591 [0.581, 0.602] | Nagelkerke's Pseudo-R²: 0.0249 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.89, 3.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608 |
| PPM001092 | PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.38 [1.328, 1.434] β: 0.322 (0.0197) |
AUROC: 0.586 [0.575, 0.597] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.26 [1.69, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608 |
| PPM001118 | PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.367 [1.31, 1.426] β: 0.312 (0.0215) |
AUROC: 0.584 [0.572, 0.598] | Nagelkerke's Pseudo-R²: 0.0215 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.73 [2.01, 3.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608 |
| PPM001119 | PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.304, 1.42] β: 0.308 (0.0217) |
AUROC: 0.586 [0.573, 0.598] | Nagelkerke's Pseudo-R²: 0.0208 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.43, 2.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608 |
| PPM001120 | PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.415] β: 0.305 (0.0215) |
AUROC: 0.584 [0.572, 0.597] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.99, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608 |
| PPM001121 | PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.305, 1.42] β: 0.308 (0.0216) |
AUROC: 0.584 [0.571, 0.596] | Nagelkerke's Pseudo-R²: 0.021 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.61, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608 |
| PPM001122 | PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.352 [1.296, 1.409] β: 0.301 (0.0213) |
AUROC: 0.579 [0.566, 0.592] | Nagelkerke's Pseudo-R²: 0.0206 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.6, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608 |
| PPM001123 | PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.31 [1.256, 1.367] β: 0.27 (0.0216) |
AUROC: 0.575 [0.562, 0.587] | Nagelkerke's Pseudo-R²: 0.0162 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608 |
| PPM001124 | PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.348 [1.293, 1.407] β: 0.299 (0.0216) |
AUROC: 0.583 [0.57, 0.595] | Nagelkerke's Pseudo-R²: 0.0197 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.57, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PT_MGI_20200608 |
| PPM001125 | PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.351 [1.296, 1.409] β: 0.301 (0.0215) |
AUROC: 0.581 [0.569, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.87, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608 |
| PPM001126 | PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.39 [1.333, 1.449] β: 0.329 (0.0214) |
AUROC: 0.586 [0.574, 0.599] | Nagelkerke's Pseudo-R²: 0.0241 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.94, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608 |
| PPM001127 | PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.417] β: 0.306 (0.0217) |
AUROC: 0.584 [0.572, 0.595] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.71, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608 |
| PPM001128 | PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.41 [1.352, 1.471] β: 0.344 (0.0216) |
AUROC: 0.591 [0.579, 0.603] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.89 [2.14, 3.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608 |
| PPM001129 | PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.399 [1.341, 1.46] β: 0.336 (0.0216) |
AUROC: 0.59 [0.578, 0.601] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.5 [2.63, 4.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608 |
| PPM001130 | PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.334 [1.264, 1.409] β: 0.289 (0.0278) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0184 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.72, 3.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608 |
| PPM001131 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.291 [1.221, 1.366] β: 0.256 (0.0286) |
AUROC: 0.575 [0.559, 0.591] | Nagelkerke's Pseudo-R²: 0.0139 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.871, 2.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608 |
| PPM018452 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Skin colour | β: -0.02375 | — | R²: 0.01374 | — | — |
| PPM018453 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: 0.04205 | — | R²: 0.02091 | — | — |
| PPM018454 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease suntan | β: -0.0266 | — | R²: 0.01362 | — | — |
| PPM018455 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease sunburn | β: 0.04289 | — | R²: 0.01118 | — | — |
| PPM018456 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: -0.62656 | — | R²: 0.03377 | — | — |
| PPM018457 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: -0.02673 | — | R²: 0.0294 | — | — |
| PPM018458 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Red hair | β: 1.77173 | — | R²: 0.05421 pseudo R²: 0.05421 |
— | — |
| PPM001132 | PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.398 [1.322, 1.477] β: 0.335 (0.0282) |
AUROC: 0.591 [0.575, 0.607] | Nagelkerke's Pseudo-R²: 0.0237 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.5 [1.68, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608 |
| PPM001133 | PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.411 [1.335, 1.491] β: 0.344 (0.0282) |
AUROC: 0.587 [0.57, 0.604] | Nagelkerke's Pseudo-R²: 0.0254 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.03, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608 |
| PPM001134 | PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.093 [1.034, 1.155] β: 0.0888 (0.0282) |
AUROC: 0.525 [0.509, 0.54] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.04, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608 |
| PPM001135 | PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.079 [1.022, 1.139] β: 0.0759 (0.0278) |
AUROC: 0.504 [0.489, 0.52] | Nagelkerke's Pseudo-R²: 0.00145 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.882, 2.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608 |
| PPM001136 | PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.144 [1.084, 1.208] β: 0.135 (0.0278) |
AUROC: 0.521 [0.506, 0.536] | Nagelkerke's Pseudo-R²: 0.00396 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.65, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608 |
| PPM001137 | PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.663 [1.57, 1.761] β: 0.508 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.53, 5.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608 |
| PPM001138 | PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608 |
| PPM001139 | PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.661 [1.568, 1.759] β: 0.507 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0489 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.79 [2.68, 5.35] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608 |
| PPM001140 | PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608 |
| PPM001141 | PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.633 [1.541, 1.729] β: 0.49 (0.0293) |
AUROC: 0.63 [0.615, 0.646] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.95 [2.79, 5.58] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608 |
| PPM001142 | PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.535 [1.493, 1.579] β: 0.429 (0.0144) |
AUROC: 0.617 [0.609, 0.625] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.11 [2.6, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608 |
| PPM001143 | PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.634 [1.542, 1.732] β: 0.491 (0.0296) |
AUROC: 0.628 [0.612, 0.644] | Nagelkerke's Pseudo-R²: 0.0457 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.86, 5.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608 |
| PPM001144 | PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.528 [1.485, 1.572] β: 0.424 (0.0144) |
AUROC: 0.615 [0.608, 0.623] | Nagelkerke's Pseudo-R²: 0.0314 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.05 [2.55, 3.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608 |
| PPM001154 | PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.09 [1.001, 1.188] β: 0.0865 (0.0437) |
AUROC: 0.524 [0.499, 0.549] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.0939 Odds Ratio (OR, top 1% vs. Rest): 1.48 [0.703, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608 |
| PPM001155 | PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.308 [1.208, 1.417] β: 0.269 (0.0407) |
AUROC: 0.557 [0.531, 0.582] | Nagelkerke's Pseudo-R²: 0.0154 Brier score: 0.093 Odds Ratio (OR, top 1% vs. Rest): 2.45 [1.34, 4.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608 |
| PPM001156 | PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.401 [1.297, 1.513] β: 0.337 (0.0393) |
AUROC: 0.569 [0.541, 0.595] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0923 Odds Ratio (OR, top 1% vs. Rest): 3.77 [2.24, 6.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608 |
| PPM001157 | PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.343 [1.266, 1.426] β: 0.295 (0.0303) |
AUROC: 0.579 [0.561, 0.597] | Nagelkerke's Pseudo-R²: 0.0204 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.49, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608 |
| PPM001158 | PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.315 [1.238, 1.398] β: 0.274 (0.0311) |
AUROC: 0.576 [0.56, 0.592] | Nagelkerke's Pseudo-R²: 0.0167 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.6 [0.981, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608 |
| PPM001159 | PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.26, 1.422] β: 0.291 (0.0308) |
AUROC: 0.58 [0.563, 0.597] | Nagelkerke's Pseudo-R²: 0.0188 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.54 [0.924, 2.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608 |
| PPM001160 | PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.349 [1.269, 1.434] β: 0.299 (0.0312) |
AUROC: 0.586 [0.57, 0.603] | Nagelkerke's Pseudo-R²: 0.0196 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.59 [0.962, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608 |
| PPM001161 | PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.365 [1.286, 1.45] β: 0.311 (0.0305) |
AUROC: 0.585 [0.569, 0.603] | Nagelkerke's Pseudo-R²: 0.0218 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.97 [1.24, 3.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608 |
| PPM001162 | PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.259, 1.421] β: 0.291 (0.0308) |
AUROC: 0.581 [0.564, 0.597] | Nagelkerke's Pseudo-R²: 0.0193 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.38, 3.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608 |
| PPM001163 | PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.411 [1.328, 1.5] β: 0.344 (0.031) |
AUROC: 0.595 [0.578, 0.611] | Nagelkerke's Pseudo-R²: 0.0257 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.31 [1.47, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608 |
| PPM001164 | PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.438 [1.354, 1.528] β: 0.364 (0.0308) |
AUROC: 0.6 [0.584, 0.616] | Nagelkerke's Pseudo-R²: 0.03 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.37 [1.54, 3.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608 |
| PPM001165 | PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.253, 1.412] β: 0.285 (0.0304) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0186 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.91 [1.2, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608 |
| PPM001166 | PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.246, 1.406] β: 0.28 (0.0307) |
AUROC: 0.578 [0.56, 0.596] | Nagelkerke's Pseudo-R²: 0.0183 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.29, 3.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608 |
| PPM001167 | PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.358 [1.279, 1.442] β: 0.306 (0.0306) |
AUROC: 0.584 [0.568, 0.601] | Nagelkerke's Pseudo-R²: 0.0212 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.43 [0.853, 2.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PT_MGI_20200608 |
| PPM001168 | PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.404 [1.322, 1.491] β: 0.339 (0.0308) |
AUROC: 0.595 [0.579, 0.61] | Nagelkerke's Pseudo-R²: 0.0264 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.05 [1.3, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608 |
| PPM001169 | PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.12 [1.056, 1.187] β: 0.113 (0.0297) |
AUROC: 0.52 [0.504, 0.538] | Nagelkerke's Pseudo-R²: 0.00286 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.817, 2.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_D05_PT_MGI_20200608 |
| PPM001170 | PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608 |
| PPM001171 | PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.4 [1.363, 1.437] β: 0.336 (0.0134) |
AUROC: 0.592 [0.585, 0.6] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.58 [2.16, 3.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608 |
| PPM001172 | PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608 |
| PPM001173 | PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.426 [1.389, 1.464] β: 0.355 (0.0134) |
AUROC: 0.598 [0.59, 0.605] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608 |
| PPM001174 | PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.254 [1.181, 1.33] β: 0.226 (0.0304) |
AUROC: 0.564 [0.547, 0.58] | Nagelkerke's Pseudo-R²: 0.012 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.05, 2.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
| PPM001175 | PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | β: 0.221 (0.0132) OR: 1.248 [1.216, 1.28] |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
| PPM001176 | PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.326 [1.246, 1.411] β: 0.282 (0.0317) |
AUROC: 0.578 [0.56, 0.594] | Nagelkerke's Pseudo-R²: 0.0179 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.13, 2.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
| PPM001177 | PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.296, 1.366] β: 0.286 (0.0134) |
AUROC: 0.579 [0.572, 0.586] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.34 [1.95, 2.82] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
| PPM001178 | PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.31 [1.234, 1.391] β: 0.27 (0.0306) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0173 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.84 [1.14, 2.97] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
| PPM001179 | PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.248 [1.216, 1.28] β: 0.221 (0.0132) |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
| PPM001180 | PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.297 [1.221, 1.377] β: 0.26 (0.0307) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0152 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.87 [1.16, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
| PPM001181 | PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.289, 1.358] β: 0.28 (0.0133) |
AUROC: 0.576 [0.568, 0.583] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.86, 2.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
| PPM001182 | PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.521 [1.43, 1.619] β: 0.42 (0.0316) |
AUROC: 0.614 [0.599, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.51, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
| PPM001183 | PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.553] β: 0.414 (0.0133) |
AUROC: 0.613 [0.606, 0.621] | Nagelkerke's Pseudo-R²: 0.0311 Brier score: 0.0815 Odds Ratio (OR, top 1% vs. Rest): 2.71 [2.28, 3.23] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
| PPM001184 | PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.708 [1.601, 1.822] β: 0.535 (0.033) |
AUROC: 0.643 [0.627, 0.658] | Nagelkerke's Pseudo-R²: 0.0603 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 3.71 [2.52, 5.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
| PPM001185 | PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.674 [1.63, 1.719] β: 0.515 (0.0137) |
AUROC: 0.64 [0.634, 0.647] | Nagelkerke's Pseudo-R²: 0.0463 Brier score: 0.0809 Odds Ratio (OR, top 1% vs. Rest): 3.64 [3.12, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
| PPM001186 | PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.564 [1.469, 1.665] β: 0.447 (0.0318) |
AUROC: 0.621 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0438 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.77, 4.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
| PPM001187 | PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.555 [1.514, 1.596] β: 0.441 (0.0135) |
AUROC: 0.621 [0.614, 0.628] | Nagelkerke's Pseudo-R²: 0.0347 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.36 [2.87, 3.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
| PPM001188 | PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.656 [1.554, 1.766] β: 0.505 (0.0326) |
AUROC: 0.634 [0.618, 0.65] | Nagelkerke's Pseudo-R²: 0.0546 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.78, 5.85] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
| PPM001189 | PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.621 [1.578, 1.665] β: 0.483 (0.0136) |
AUROC: 0.631 [0.624, 0.638] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.86 [3.31, 4.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
| PPM001190 | PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.584 [1.488, 1.686] β: 0.46 (0.0318) |
AUROC: 0.625 [0.609, 0.641] | Nagelkerke's Pseudo-R²: 0.0462 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.24, 4.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
| PPM001191 | PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.567 [1.526, 1.609] β: 0.449 (0.0134) |
AUROC: 0.622 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.0361 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.69 [3.16, 4.31] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
| PPM001192 | PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.772 [1.659, 1.891] β: 0.572 (0.0334) |
AUROC: 0.651 [0.635, 0.666] | Nagelkerke's Pseudo-R²: 0.0661 Brier score: 0.133 Odds Ratio (OR, top 1% vs. Rest): 3.22 [2.15, 4.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
| PPM001193 | PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.756 [1.709, 1.804] β: 0.563 (0.0138) |
AUROC: 0.652 [0.645, 0.658] | Nagelkerke's Pseudo-R²: 0.0548 Brier score: 0.0805 Odds Ratio (OR, top 1% vs. Rest): 4.38 [3.79, 5.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
| PPM001194 | PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.643 [1.542, 1.75] β: 0.496 (0.0323) |
AUROC: 0.635 [0.618, 0.651] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 2.84 [1.88, 4.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608 |
| PPM001195 | PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.612 [1.57, 1.656] β: 0.478 (0.0136) |
AUROC: 0.63 [0.623, 0.637] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.83, 3.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608 |
| PPM001196 | PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.7 [1.594, 1.813] β: 0.53 (0.0328) |
AUROC: 0.641 [0.625, 0.656] | Nagelkerke's Pseudo-R²: 0.0592 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 2.48 [1.63, 3.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
| PPM001197 | PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.699 [1.654, 1.746] β: 0.53 (0.0138) |
AUROC: 0.643 [0.637, 0.65] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.0807 Odds Ratio (OR, top 1% vs. Rest): 4.02 [3.46, 4.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
| PPM001198 | PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.402 [1.32, 1.489] β: 0.338 (0.0307) |
AUROC: 0.595 [0.577, 0.612] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.12, 2.91] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608 |
| PPM001199 | PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.391 [1.309, 1.478] β: 0.33 (0.031) |
AUROC: 0.59 [0.573, 0.607] | Nagelkerke's Pseudo-R²: 0.0248 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.12, 2.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608 |
| PPM001200 | PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.453 [1.367, 1.544] β: 0.374 (0.0311) |
AUROC: 0.605 [0.588, 0.621] | Nagelkerke's Pseudo-R²: 0.0307 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.31, 3.32] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608 |
| PPM001201 | PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.477 [1.39, 1.57] β: 0.39 (0.031) |
AUROC: 0.609 [0.592, 0.624] | Nagelkerke's Pseudo-R²: 0.034 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.21, 3.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608 |
| PPM001202 | PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.229 [1.157, 1.305] β: 0.206 (0.0306) |
AUROC: 0.55 [0.533, 0.566] | Nagelkerke's Pseudo-R²: 0.0097 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.17, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
| PPM001203 | PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.18 [1.15, 1.21] β: 0.165 (0.0131) |
AUROC: 0.542 [0.534, 0.55] | Nagelkerke's Pseudo-R²: 0.00504 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.49 [1.2, 1.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
| PPM001204 | PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.151 [1.084, 1.221] β: 0.14 (0.0305) |
AUROC: 0.539 [0.52, 0.556] | Nagelkerke's Pseudo-R²: 0.00453 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.51 [0.907, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
| PPM001205 | PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.188 [1.158, 1.22] β: 0.172 (0.0133) |
AUROC: 0.549 [0.542, 0.556] | Nagelkerke's Pseudo-R²: 0.00537 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.82 [1.48, 2.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
| PPM001206 | PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.22 [1.149, 1.295] β: 0.199 (0.0304) |
AUROC: 0.548 [0.53, 0.564] | Nagelkerke's Pseudo-R²: 0.00934 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.18, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
| PPM001207 | PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.201 [1.171, 1.233] β: 0.183 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.00619 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.73 [1.41, 2.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
| PPM001208 | PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.225 [1.155, 1.299] β: 0.203 (0.0301) |
AUROC: 0.546 [0.529, 0.562] | Nagelkerke's Pseudo-R²: 0.00979 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 2.11 [1.34, 3.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
| PPM001209 | PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.2 [1.169, 1.231] β: 0.182 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.0061 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.4, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
| PPM001210 | PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.427 [1.343, 1.516] β: 0.356 (0.0309) |
AUROC: 0.597 [0.58, 0.614] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.28 [1.46, 3.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
| PPM001211 | PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.424 [1.387, 1.461] β: 0.353 (0.0132) |
AUROC: 0.597 [0.59, 0.604] | Nagelkerke's Pseudo-R²: 0.0228 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.19] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
| PPM001212 | PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.509 [1.418, 1.605] β: 0.411 (0.0314) |
AUROC: 0.613 [0.595, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.55, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
| PPM001213 | PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.554] β: 0.414 (0.0136) |
AUROC: 0.614 [0.607, 0.62] | Nagelkerke's Pseudo-R²: 0.0303 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 2.98 [2.52, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
| PPM001214 | PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.43 [1.346, 1.52] β: 0.358 (0.0311) |
AUROC: 0.597 [0.58, 0.612] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.98 [1.98, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
| PPM001215 | PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.441 [1.404, 1.479] β: 0.365 (0.0132) |
AUROC: 0.6 [0.593, 0.608] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.92 [2.47, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
| PPM001216 | PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.501 [1.411, 1.596] β: 0.406 (0.0314) |
AUROC: 0.61 [0.594, 0.626] | Nagelkerke's Pseudo-R²: 0.037 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.29 [1.47, 3.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
| PPM001217 | PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.49 [1.451, 1.529] β: 0.399 (0.0134) |
AUROC: 0.608 [0.601, 0.615] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 3.0 [2.54, 3.54] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
| PPM001218 | PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.489 [1.401, 1.583] β: 0.398 (0.0312) |
AUROC: 0.607 [0.591, 0.623] | Nagelkerke's Pseudo-R²: 0.0354 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.63, 3.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
| PPM001219 | PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.443 [1.406, 1.481] β: 0.367 (0.0132) |
AUROC: 0.601 [0.594, 0.608] | Nagelkerke's Pseudo-R²: 0.0246 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.5 [2.09, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
| PPM001220 | PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.568 [1.473, 1.668] β: 0.45 (0.0317) |
AUROC: 0.622 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0443 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 3.43 [2.32, 5.05] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
| PPM001221 | PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.571 [1.53, 1.614] β: 0.452 (0.0136) |
AUROC: 0.623 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.036 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.54 [3.02, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
| PPM001222 | PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.498 [1.408, 1.593] β: 0.404 (0.0314) |
AUROC: 0.609 [0.592, 0.626] | Nagelkerke's Pseudo-R²: 0.0353 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.44 [2.31, 5.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608 |
| PPM001223 | PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.448 [1.411, 1.486] β: 0.37 (0.0132) |
AUROC: 0.602 [0.594, 0.609] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.78 [2.34, 3.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608 |
| PPM001224 | PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.585 [1.489, 1.687] β: 0.46 (0.0319) |
AUROC: 0.624 [0.607, 0.641] | Nagelkerke's Pseudo-R²: 0.0464 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.49 [1.61, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
| PPM001225 | PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.528 [1.489, 1.569] β: 0.424 (0.0134) |
AUROC: 0.615 [0.607, 0.622] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.55 [3.04, 4.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
| PPM001670 | PGS000730 (PRS_BCC) |
PSS000871| European Ancestry| 88,924 individuals |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Reported Trait: Basal cell carcinoma | OR: 1.57 [1.55, 1.6] | AUROC: 0.624 | — | — | — |
| PPM001761 | PGS000738 (CONFIRMED_PGS) |
PSS000907| European Ancestry| 4,008 individuals |
PGP000145 | Roberts GHL et al. Am J Hum Genet (2019) |
Reported Trait: Vitiligo | — | — | Odds Ratio (OR, top 20% vs remaining 80% of score distribution): 4.87 [4.21, 5.64] | — | — |
| PPM001762 | PGS000738 (CONFIRMED_PGS) |
PSS000907| European Ancestry| 4,008 individuals |
PGP000145 | Roberts GHL et al. Am J Hum Genet (2019) |
Reported Trait: Vitiligo | — | — | Odds Ratio (OR, top 10% vs remaining 90% of score distribution): 5.26 [4.42, 6.29] | — | — |
| PPM001763 | PGS000738 (CONFIRMED_PGS) |
PSS000907| European Ancestry| 4,008 individuals |
PGP000145 | Roberts GHL et al. Am J Hum Genet (2019) |
Reported Trait: Vitiligo | — | — | Odds Ratio (OR, top 10% vs remaining 95% of score distribution): 6.2 [4.96, 7.79] | — | — |
| PPM001764 | PGS000738 (CONFIRMED_PGS) |
PSS000907| European Ancestry| 4,008 individuals |
PGP000145 | Roberts GHL et al. Am J Hum Genet (2019) |
Reported Trait: Vitiligo | — | — | Odds Ratio (OR, top 1% vs remaining 99% of score distribution): 8.79 [5.85, 13.78] | — | — |
| PPM018437 | PGS000738 (CONFIRMED_PGS) |
PSS010969| European Ancestry| 4,945 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: 0.02234 | — | R²: 0.02897 | — | — |
| PPM018438 | PGS000738 (CONFIRMED_PGS) |
PSS010968| European Ancestry| 4,702 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Red hair | β: 0.69478 | — | pseudo R²: 0.03857 | — | — |
| PPM018435 | PGS000738 (CONFIRMED_PGS) |
PSS010977| European Ancestry| 4,987 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: -0.04382 | — | R²: 0.02103 | — | — |
| PPM018436 | PGS000738 (CONFIRMED_PGS) |
PSS010974| European Ancestry| 4,979 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: 0.4039 | — | R²: 0.03252 | — | — |
| PPM001935 | PGS000760 (VIT) |
PSS000970| European Ancestry| 1,584 individuals |
PGP000164 | Khan Z et al. Nat Commun (2021) |
Reported Trait: anti-PD-L1 induced hypothyroidism in cancer patients | HR: 1.41 [1.22, 1.61] | — | meta-analysis p-value: 1.10e-06 | 5 genotype PCs | — |
| PPM001963 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma | — | — | Hazard Ratio (HR, top 20% vs bottom 20%): 2.51 [1.28, 4.92] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001964 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma (males) | — | — | Hazard Ratio (HR, top 20% vs bottom 20%): 3.7 [1.37, 9.98] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001965 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma (males) | — | — | Hazard Ratio (HR, middle 60% vs bottom 20%): 2.61 [1.03, 6.63] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001966 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma | OR: 1.55 [1.42, 1.69] | AUROC: 0.64 [0.62, 0.66] | Odds Ratio (OR, top 20% vs bottom 20%): 3.66 [2.69, 5.05] | Sex, family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001967 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma (males) | OR: 1.39 [1.23, 1.57] | — | — | Family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001968 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma (females) | OR: 1.72 [1.53, 1.94] | — | — | Family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001962 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma | HR: 1.46 [1.2, 1.77] | C-index: 0.643 [0.584, 0.702] | — | Sex, melanoma family history, treatment (aspirin/placebo), age at enrolment, PRS*treatment | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM002005 | PGS000773 (PRS179_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Breast cancer | OR: 1.26 [1.22, 1.3] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002006 | PGS000773 (PRS179_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Breast cancer | — | AUROC: 0.568 [0.56, 0.576] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002007 | PGS000774 (PRS179_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.33 [1.27, 1.38] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002008 | PGS000774 (PRS179_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.576 [0.566, 0.585] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002009 | PGS000775 (PRS179_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor negative breast cancer | OR: 1.31 [1.24, 1.37] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002010 | PGS000775 (PRS179_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor negative breast cancer | — | AUROC: 0.578 [0.564, 0.591] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002054 | PGS000783 (CC_Breast_IV) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | HR: 1.52 [1.47, 1.56] | AUROC: 0.637 C-index: 0.635 (0.004) |
R²: 0.146 | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity( ≥1 live birth vs. none), age at menarche, body mass index, menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use, alcool intake, (Body mass index)*(menopausal status) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002070 | PGS000783 (CC_Breast_IV) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | — | AUROC: 0.626 C-index: 0.62 (0.005) |
R²: 0.122 | Age, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002456 | PGS000873 (SNP143) |
PSS001111| Ancestry Not Reported| 2,073 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.12 [1.81, 2.49] | Age | — |
| PPM002458 | PGS000873 (SNP143) |
PSS001105| Ancestry Not Reported| 2,021 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.17 [1.83, 2.58] | Age | — |
| PPM002460 | PGS000873 (SNP143) |
PSS001108| Ancestry Not Reported| 1,707 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.86 [1.18, 2.91] | Age | — |
| PPM002462 | PGS000873 (SNP143) |
PSS001113| Ancestry Not Reported| 1,991 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.14 [1.79, 2.55] | Age | — |
| PPM002464 | PGS000873 (SNP143) |
PSS001112| Ancestry Not Reported| 1,750 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 2.0 [1.46, 2.75] | Age | — |
| PPM002466 | PGS000873 (SNP143) |
PSS001107| Ancestry Not Reported| 1,956 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.55 [1.86, 2.7] | Age | — |
| PPM002468 | PGS000873 (SNP143) |
PSS001106| Ancestry Not Reported| 1,733 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.84 [1.3, 2.6] | Age | — |
| PPM002470 | PGS000873 (SNP143) |
PSS001110| Ancestry Not Reported| 1,694 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.44 [0.84, 2.47] | Age | — |
| PPM002471 | PGS000873 (SNP143) |
PSS001109| Ancestry Not Reported| 1,681 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 3.12 [1.41, 6.88] | Age | — |
| PPM002457 | PGS000873 (SNP143) |
PSS001111| Ancestry Not Reported| 2,073 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.06 [1.75, 2.42] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002459 | PGS000873 (SNP143) |
PSS001105| Ancestry Not Reported| 2,021 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.11 [1.78, 2.51] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002461 | PGS000873 (SNP143) |
PSS001108| Ancestry Not Reported| 1,707 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.81 [1.16, 2.84] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002463 | PGS000873 (SNP143) |
PSS001113| Ancestry Not Reported| 1,991 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.07 [1.74, 2.48] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002465 | PGS000873 (SNP143) |
PSS001112| Ancestry Not Reported| 1,750 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.93 [1.41, 2.65] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002469 | PGS000873 (SNP143) |
PSS001106| Ancestry Not Reported| 1,733 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.77 [1.24, 2.51] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002472 | PGS000873 (SNP143) |
PSS001109| Ancestry Not Reported| 1,681 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 2.99 [1.35, 6.6] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002467 | PGS000873 (SNP143) |
PSS001107| Ancestry Not Reported| 1,956 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.18 [1.81, 2.63] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM018697 | PGS000873 (SNP143) |
PSS011069| East Asian Ancestry| 495 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.58, 0.63] | Hazard ratio (HR, high vs low tertile): 2.68 [1.97, 3.66] | age at recruitment | — |
| PPM007462 | PGS000927 (GBE_HC1158) |
PSS004153| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE other dermatitis | — | AUROC: 0.61027 [0.57953, 0.64101] | R²: 0.02035 Incremental AUROC (full-covars): 0.00207 PGS R2 (no covariates): 0.00268 PGS AUROC (no covariates): 0.5378 [0.50673, 0.56886] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007463 | PGS000927 (GBE_HC1158) |
PSS004154| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE other dermatitis | — | AUROC: 0.57706 [0.52927, 0.62486] | R²: 0.02951 Incremental AUROC (full-covars): 0.01147 PGS R2 (no covariates): 0.00458 PGS AUROC (no covariates): 0.5429 [0.49389, 0.59191] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007464 | PGS000927 (GBE_HC1158) |
PSS004155| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE other dermatitis | — | AUROC: 0.54587 [0.53304, 0.5587] | R²: 0.00506 Incremental AUROC (full-covars): 0.01785 PGS R2 (no covariates): 0.00339 PGS AUROC (no covariates): 0.53939 [0.52639, 0.55239] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007465 | PGS000927 (GBE_HC1158) |
PSS004156| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE other dermatitis | — | AUROC: 0.58261 [0.56273, 0.60248] | R²: 0.01573 Incremental AUROC (full-covars): 0.00482 PGS R2 (no covariates): 0.00187 PGS AUROC (no covariates): 0.52627 [0.50591, 0.54663] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007466 | PGS000927 (GBE_HC1158) |
PSS004157| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE other dermatitis | — | AUROC: 0.56752 [0.56014, 0.57491] | R²: 0.01047 Incremental AUROC (full-covars): 0.01697 PGS R2 (no covariates): 0.00542 PGS AUROC (no covariates): 0.54889 [0.54154, 0.55624] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007546 | PGS000944 (GBE_HC261) |
PSS004384| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Eczema/dermatitis | — | AUROC: 0.62856 [0.58377, 0.67334] | R²: 0.02337 Incremental AUROC (full-covars): 0.00187 PGS R2 (no covariates): 0.00173 PGS AUROC (no covariates): 0.52778 [0.48039, 0.57516] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007547 | PGS000944 (GBE_HC261) |
PSS004385| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Eczema/dermatitis | — | AUROC: 0.59588 [0.52553, 0.66622] | R²: 0.02855 Incremental AUROC (full-covars): 0.02432 PGS R2 (no covariates): 0.0116 PGS AUROC (no covariates): 0.58664 [0.52213, 0.65115] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007548 | PGS000944 (GBE_HC261) |
PSS004386| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Eczema/dermatitis | — | AUROC: 0.56459 [0.54541, 0.58377] | R²: 0.00802 Incremental AUROC (full-covars): 0.01208 PGS R2 (no covariates): 0.00353 PGS AUROC (no covariates): 0.54597 [0.52632, 0.56561] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007549 | PGS000944 (GBE_HC261) |
PSS004387| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Eczema/dermatitis | — | AUROC: 0.56106 [0.52439, 0.59773] | R²: 0.00683 Incremental AUROC (full-covars): -0.0012 PGS R2 (no covariates): 0.00011 PGS AUROC (no covariates): 0.51686 [0.48122, 0.5525] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007550 | PGS000944 (GBE_HC261) |
PSS004388| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Eczema/dermatitis | — | AUROC: 0.57099 [0.55943, 0.58256] | R²: 0.00884 Incremental AUROC (full-covars): 0.02521 PGS R2 (no covariates): 0.00527 PGS AUROC (no covariates): 0.5556 [0.54396, 0.56724] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007639 | PGS000963 (GBE_HC1184) |
PSS004168| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE follicular cysts of skin and subcutaneous tissue | — | AUROC: 0.56399 [0.51489, 0.61308] | R²: 0.01027 Incremental AUROC (full-covars): -0.00108 PGS R2 (no covariates): 0.00011 PGS AUROC (no covariates): 0.51899 [0.4747, 0.56328] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007640 | PGS000963 (GBE_HC1184) |
PSS004169| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE follicular cysts of skin and subcutaneous tissue | — | AUROC: 0.64299 [0.54406, 0.74191] | R²: 0.02377 Incremental AUROC (full-covars): 0.01591 PGS R2 (no covariates): 0.00898 PGS AUROC (no covariates): 0.60189 [0.51478, 0.689] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007641 | PGS000963 (GBE_HC1184) |
PSS004170| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE follicular cysts of skin and subcutaneous tissue | — | AUROC: 0.61353 [0.59056, 0.63651] | R²: 0.02635 Incremental AUROC (full-covars): 0.0691 PGS R2 (no covariates): 0.02281 PGS AUROC (no covariates): 0.59346 [0.56998, 0.61695] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007642 | PGS000963 (GBE_HC1184) |
PSS004171| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE follicular cysts of skin and subcutaneous tissue | — | AUROC: 0.64204 [0.6008, 0.68328] | R²: 0.03504 Incremental AUROC (full-covars): 0.04562 PGS R2 (no covariates): 0.02125 PGS AUROC (no covariates): 0.56287 [0.51348, 0.61226] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007643 | PGS000963 (GBE_HC1184) |
PSS004172| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE follicular cysts of skin and subcutaneous tissue | — | AUROC: 0.6146 [0.60131, 0.6279] | R²: 0.02902 Incremental AUROC (full-covars): 0.06632 PGS R2 (no covariates): 0.02439 PGS AUROC (no covariates): 0.58761 [0.57398, 0.60124] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007818 | PGS001011 (GBE_HC534) |
PSS004521| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE viral warts | — | AUROC: 0.62763 [0.56904, 0.68622] | R²: 0.01913 Incremental AUROC (full-covars): -0.00455 PGS R2 (no covariates): 0.00116 PGS AUROC (no covariates): 0.48242 [0.41987, 0.54497] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007819 | PGS001011 (GBE_HC534) |
PSS004522| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE viral warts | — | AUROC: 0.65545 [0.57671, 0.73418] | R²: 0.03677 Incremental AUROC (full-covars): -0.00026 PGS R2 (no covariates): 1e-05 PGS AUROC (no covariates): 0.50846 [0.40705, 0.60986] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007820 | PGS001011 (GBE_HC534) |
PSS004523| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE viral warts | — | AUROC: 0.56023 [0.54032, 0.58015] | R²: 0.0051 Incremental AUROC (full-covars): 0.01103 PGS R2 (no covariates): 0.00154 PGS AUROC (no covariates): 0.53437 [0.51402, 0.55472] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007821 | PGS001011 (GBE_HC534) |
PSS004524| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE viral warts | — | AUROC: 0.5793 [0.54592, 0.61268] | R²: 0.01114 Incremental AUROC (full-covars): 0.00245 PGS R2 (no covariates): 0.00048 PGS AUROC (no covariates): 0.51036 [0.47743, 0.54328] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007822 | PGS001011 (GBE_HC534) |
PSS004525| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE viral warts | — | AUROC: 0.56004 [0.54811, 0.57198] | R²: 0.00576 Incremental AUROC (full-covars): 0.00636 PGS R2 (no covariates): 0.00167 PGS AUROC (no covariates): 0.53057 [0.51862, 0.54252] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007958 | PGS001040 (GBE_cancer1060) |
PSS007651| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.80478 [0.72556, 0.884] | R²: 0.07029 Incremental AUROC (full-covars): -0.00066 PGS R2 (no covariates): 0.00133 PGS AUROC (no covariates): 0.54127 [0.39017, 0.69237] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007959 | PGS001040 (GBE_cancer1060) |
PSS007652| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.86455 [0.80574, 0.92335] | R²: 0.12918 Incremental AUROC (full-covars): -0.00442 PGS R2 (no covariates): 0.00152 PGS AUROC (no covariates): 0.4523 [0.1694, 0.73519] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007960 | PGS001040 (GBE_cancer1060) |
PSS007653| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.73342 [0.72065, 0.74619] | R²: 0.10751 Incremental AUROC (full-covars): 0.0378 PGS R2 (no covariates): 0.05185 PGS AUROC (no covariates): 0.66327 [0.64889, 0.67765] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007961 | PGS001040 (GBE_cancer1060) |
PSS007654| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.76366 [0.66832, 0.85901] | R²: 0.06447 Incremental AUROC (full-covars): -0.00934 PGS R2 (no covariates): 0.00078 PGS AUROC (no covariates): 0.47181 [0.35611, 0.58752] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007962 | PGS001040 (GBE_cancer1060) |
PSS007655| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.70656 [0.69863, 0.7145] | R²: 0.08615 Incremental AUROC (full-covars): 0.04717 PGS R2 (no covariates): 0.03949 PGS AUROC (no covariates): 0.64209 [0.6334, 0.65078] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM018463 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease sunburn | β: 0.08836 | — | R²: 0.01475 | — | — |
| PPM018465 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: -0.0689 | — | R²: 0.03786 | — | — |
| PPM018459 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Eye colour | β: -0.11302 | — | R²: 0.0106 | — | — |
| PPM018460 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Skin colour | β: -0.05462 | — | R²: 0.01757 | — | — |
| PPM018461 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: 0.09955 | — | R²: 0.02643 | — | — |
| PPM018462 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease suntan | β: -0.06804 | — | R²: 0.01892 | — | — |
| PPM018464 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: -1.51455 | — | R²: 0.04441 | — | — |
| PPM018466 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Blond hair | β: 1.14835 | — | pseudo R²: 0.01006 | — | — |
| PPM007963 | PGS001041 (GBE_cancer1003) |
PSS007621| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.78777 [0.7126, 0.86293] | R²: 0.06151 Incremental AUROC (full-covars): 0.00386 PGS R2 (no covariates): 0.00103 PGS AUROC (no covariates): 0.5229 [0.37426, 0.67153] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007964 | PGS001041 (GBE_cancer1003) |
PSS007622| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.83061 [0.75233, 0.9089] | R²: 0.10839 Incremental AUROC (full-covars): 0.0017 PGS R2 (no covariates): 0.00376 PGS AUROC (no covariates): 0.56985 [0.36492, 0.77477] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007965 | PGS001041 (GBE_cancer1003) |
PSS007623| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.71667 [0.70431, 0.72902] | R²: 0.09613 Incremental AUROC (full-covars): 0.03439 PGS R2 (no covariates): 0.04566 PGS AUROC (no covariates): 0.65086 [0.63722, 0.6645] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007966 | PGS001041 (GBE_cancer1003) |
PSS007624| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.76232 [0.67332, 0.85131] | R²: 0.07091 Incremental AUROC (full-covars): -0.01012 PGS R2 (no covariates): 6e-05 PGS AUROC (no covariates): 0.49291 [0.37897, 0.60686] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007967 | PGS001041 (GBE_cancer1003) |
PSS007625| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.6935 [0.68584, 0.70116] | R²: 0.07834 Incremental AUROC (full-covars): 0.04393 PGS R2 (no covariates): 0.03573 PGS AUROC (no covariates): 0.63289 [0.62459, 0.64118] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008383 | PGS001131 (GBE_HC530) |
PSS004516| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE zoster [herpes zoster] | — | AUROC: 0.66564 [0.59848, 0.7328] | R²: 0.02855 Incremental AUROC (full-covars): 0.00653 PGS R2 (no covariates): 0.00463 PGS AUROC (no covariates): 0.5717 [0.50786, 0.63553] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008384 | PGS001131 (GBE_HC530) |
PSS004517| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE zoster [herpes zoster] | — | AUROC: 0.6496 [0.5711, 0.7281] | R²: 0.02884 Incremental AUROC (full-covars): 0.00319 PGS R2 (no covariates): 1e-05 PGS AUROC (no covariates): 0.49296 [0.39896, 0.58695] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008385 | PGS001131 (GBE_HC530) |
PSS004518| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE zoster [herpes zoster] | — | AUROC: 0.61339 [0.59385, 0.63293] | R²: 0.01934 Incremental AUROC (full-covars): 0.00397 PGS R2 (no covariates): 0.00108 PGS AUROC (no covariates): 0.52734 [0.50543, 0.54926] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008386 | PGS001131 (GBE_HC530) |
PSS004519| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE zoster [herpes zoster] | — | AUROC: 0.64482 [0.60407, 0.68558] | R²: 0.02792 Incremental AUROC (full-covars): -0.00388 PGS R2 (no covariates): 0.00012 PGS AUROC (no covariates): 0.49268 [0.44738, 0.53799] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008387 | PGS001131 (GBE_HC530) |
PSS004520| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE zoster [herpes zoster] | — | AUROC: 0.60947 [0.59775, 0.62119] | R²: 0.0198 Incremental AUROC (full-covars): 0.00787 PGS R2 (no covariates): 0.00329 PGS AUROC (no covariates): 0.54558 [0.53361, 0.55755] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008427 | PGS001140 (GBE_HC1190) |
PSS004178| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE seborrhoeic keratosis | — | AUROC: 0.69791 [0.62772, 0.7681] | R²: 0.0531 Incremental AUROC (full-covars): 0.01676 PGS R2 (no covariates): 0.01004 PGS AUROC (no covariates): 0.5859 [0.50622, 0.66558] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008428 | PGS001140 (GBE_HC1190) |
PSS004179| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE seborrhoeic keratosis | — | AUROC: 0.74674 [0.66312, 0.83035] | R²: 0.10541 Incremental AUROC (full-covars): -0.00457 PGS R2 (no covariates): 0.01744 PGS AUROC (no covariates): 0.62007 [0.51848, 0.72165] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008429 | PGS001140 (GBE_HC1190) |
PSS004180| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE seborrhoeic keratosis | — | AUROC: 0.63238 [0.61781, 0.64695] | R²: 0.03162 Incremental AUROC (full-covars): 0.01328 PGS R2 (no covariates): 0.00595 PGS AUROC (no covariates): 0.55636 [0.54088, 0.57185] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008430 | PGS001140 (GBE_HC1190) |
PSS004181| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE seborrhoeic keratosis | — | AUROC: 0.65125 [0.6056, 0.6969] | Incremental AUROC (full-covars): 0.00972 R²: 0.03155 PGS R2 (no covariates): 0.00354 PGS AUROC (no covariates): 0.54802 [0.49607, 0.59996] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008431 | PGS001140 (GBE_HC1190) |
PSS004182| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE seborrhoeic keratosis | — | AUROC: 0.62735 [0.61905, 0.63565] | R²: 0.03214 Incremental AUROC (full-covars): 0.01502 PGS R2 (no covariates): 0.00744 PGS AUROC (no covariates): 0.56248 [0.55356, 0.57141] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008790 | PGS001257 (GBE_INI1737) |
PSS004876| African Ancestry| 5,650 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Childhood sunburn | — | — | R²: 9e-05 [-0.00037, 0.00054] Incremental R2 (full-covars): -0.00203 PGS R2 (no covariates): 0.0 [-0.00007, 0.00008] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008791 | PGS001257 (GBE_INI1737) |
PSS004877| East Asian Ancestry| 1,297 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Childhood sunburn | — | — | R²: 0.01343 [0.0026, 0.02427] Incremental R2 (full-covars): 0.00126 PGS R2 (no covariates): 0.00125 [-0.0021, 0.0046] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008792 | PGS001257 (GBE_INI1737) |
PSS004878| European Ancestry| 19,358 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Childhood sunburn | — | — | R²: 0.03588 [0.03135, 0.04042] Incremental R2 (full-covars): 0.01262 PGS R2 (no covariates): 0.01397 [0.01107, 0.01686] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008793 | PGS001257 (GBE_INI1737) |
PSS004879| South Asian Ancestry| 6,219 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Childhood sunburn | — | — | R²: 0.00339 [0.00082, 0.00595] Incremental R2 (full-covars): -0.00105 PGS R2 (no covariates): 0.00105 [-0.00038, 0.00249] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008794 | PGS001257 (GBE_INI1737) |
PSS004880| European Ancestry| 50,754 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Childhood sunburn | — | — | R²: 0.00954 [0.00808, 0.011] Incremental R2 (full-covars): 0.00533 PGS R2 (no covariates): 0.00558 [0.00446, 0.0067] |
age, sex, UKB array type, Genotype PCs | — |
| PPM009053 | PGS001312 (GBE_HC38) |
PSS004471| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Psoriasis | — | AUROC: 0.73107 [0.60624, 0.85591] | R²: 0.06593 Incremental AUROC (full-covars): 0.0282 PGS R2 (no covariates): 0.01927 PGS AUROC (no covariates): 0.62557 [0.48848, 0.76266] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009054 | PGS001312 (GBE_HC38) |
PSS004472| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Psoriasis | — | AUROC: 0.88867 [0.80531, 0.97202] | R²: 0.24575 Incremental AUROC (full-covars): 0.01187 PGS R2 (no covariates): 0.00399 PGS AUROC (no covariates): 0.57774 [0.40533, 0.75016] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009055 | PGS001312 (GBE_HC38) |
PSS004473| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Psoriasis | — | AUROC: 0.68424 [0.65757, 0.71091] | R²: 0.05057 Incremental AUROC (full-covars): 0.0981 PGS R2 (no covariates): 0.04137 PGS AUROC (no covariates): 0.66409 [0.63596, 0.69222] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009056 | PGS001312 (GBE_HC38) |
PSS004474| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Psoriasis | — | AUROC: 0.6849 [0.63397, 0.73584] | R²: 0.0448 Incremental AUROC (full-covars): 0.052 PGS R2 (no covariates): 0.02087 PGS AUROC (no covariates): 0.64825 [0.59861, 0.6979] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009057 | PGS001312 (GBE_HC38) |
PSS004475| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Psoriasis | — | AUROC: 0.69754 [0.68165, 0.71343] | R²: 0.05574 Incremental AUROC (full-covars): 0.14505 PGS R2 (no covariates): 0.05226 PGS AUROC (no covariates): 0.69158 [0.6754, 0.70775] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009058 | PGS001313 (GBE_HC1159) |
PSS004158| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE psoriasis | — | AUROC: 0.69906 [0.60273, 0.7954] | R²: 0.04185 Incremental AUROC (full-covars): 0.01899 PGS R2 (no covariates): 0.00732 PGS AUROC (no covariates): 0.62223 [0.54291, 0.70154] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009059 | PGS001313 (GBE_HC1159) |
PSS004159| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE psoriasis | — | AUROC: 0.72306 [0.61623, 0.82989] | R²: 0.09162 Incremental AUROC (full-covars): 0.00222 PGS R2 (no covariates): 0.00378 PGS AUROC (no covariates): 0.48492 [0.37014, 0.5997] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009060 | PGS001313 (GBE_HC1159) |
PSS004160| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE psoriasis | — | AUROC: 0.66545 [0.64532, 0.68558] | R²: 0.04468 Incremental AUROC (full-covars): 0.07449 PGS R2 (no covariates): 0.0337 PGS AUROC (no covariates): 0.64565 [0.62471, 0.66658] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009061 | PGS001313 (GBE_HC1159) |
PSS004161| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE psoriasis | — | AUROC: 0.63418 [0.59417, 0.67419] | R²: 0.0236 Incremental AUROC (full-covars): 0.05154 PGS R2 (no covariates): 0.0123 PGS AUROC (no covariates): 0.60455 [0.56482, 0.64428] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009062 | PGS001313 (GBE_HC1159) |
PSS004162| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE psoriasis | — | AUROC: 0.67543 [0.66285, 0.68801] | R²: 0.05117 Incremental AUROC (full-covars): 0.13853 PGS R2 (no covariates): 0.04966 PGS AUROC (no covariates): 0.6729 [0.66027, 0.68553] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009166 | PGS001336 (GBE_cancer1002) |
PSS007616| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.79293 [0.76728, 0.81858] | R²: 0.15047 Incremental AUROC (full-covars): 0.01474 PGS R2 (no covariates): 0.00598 PGS AUROC (no covariates): 0.56918 [0.51783, 0.62054] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009167 | PGS001336 (GBE_cancer1002) |
PSS007617| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.7602 [0.71475, 0.80565] | R²: 0.14344 Incremental AUROC (full-covars): 0.01509 PGS R2 (no covariates): 0.01507 PGS AUROC (no covariates): 0.59411 [0.51563, 0.67258] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009168 | PGS001336 (GBE_cancer1002) |
PSS007618| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.80561 [0.79545, 0.81577] | R²: 0.18447 Incremental AUROC (full-covars): 0.01345 PGS R2 (no covariates): 0.01264 PGS AUROC (no covariates): 0.58544 [0.56669, 0.6042] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009169 | PGS001336 (GBE_cancer1002) |
PSS007619| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.83564 [0.81289, 0.85838] | R²: 0.18535 Incremental AUROC (full-covars): 0.00869 PGS R2 (no covariates): 0.00739 PGS AUROC (no covariates): 0.5725 [0.52745, 0.61755] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009170 | PGS001336 (GBE_cancer1002) |
PSS007620| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.80961 [0.80348, 0.81573] | R²: 0.1894 Incremental AUROC (full-covars): 0.02139 PGS R2 (no covariates): 0.01602 PGS AUROC (no covariates): 0.59627 [0.58498, 0.60756] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005215 | PGS001536 (GBE_HC1188) |
PSS004173| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vitiligo | — | AUROC: 0.63509 [0.52563, 0.74454] | R²: 0.01654 Incremental AUROC (full-covars): -0.00281 PGS R2 (no covariates): 0.0 PGS AUROC (no covariates): 0.51169 [0.39527, 0.62811] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005216 | PGS001536 (GBE_HC1188) |
PSS004174| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vitiligo | — | AUROC: 0.82774 [0.75298, 0.90249] | R²: 0.08055 Incremental AUROC (full-covars): 0.01924 PGS R2 (no covariates): 0.00431 PGS AUROC (no covariates): 0.57823 [0.37976, 0.7767] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005217 | PGS001536 (GBE_HC1188) |
PSS004175| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vitiligo | — | AUROC: 0.6991 [0.61917, 0.77902] | R²: 0.03993 Incremental AUROC (full-covars): 0.01341 PGS R2 (no covariates): 0.00254 PGS AUROC (no covariates): 0.55625 [0.47549, 0.63701] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005218 | PGS001536 (GBE_HC1188) |
PSS004176| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vitiligo | — | AUROC: 0.64566 [0.58746, 0.70386] | R²: 0.02575 Incremental AUROC (full-covars): 0.0309 PGS R2 (no covariates): 0.01048 PGS AUROC (no covariates): 0.60302 [0.5391, 0.66694] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005219 | PGS001536 (GBE_HC1188) |
PSS004177| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vitiligo | — | AUROC: 0.63449 [0.58754, 0.68144] | R²: 0.01686 Incremental AUROC (full-covars): 0.08163 PGS R2 (no covariates): 0.01621 PGS AUROC (no covariates): 0.64193 [0.59907, 0.68478] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009229 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Moderate-to-severe aotpic dermatitis | — | AUROC: 0.93 | R²: 0.49 | Age, sex, father's ethnicity, mother ethnicity | Nagelkerke's R^2, only unrelated individuals were considered in the analyses |
| PPM009230 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Food allergy | — | AUROC: 0.75 | — | Age, sex, father's ethnicity, mother ethnicity | Only unrelated individuals were considered in the analyses |
| PPM009231 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Allergic asthma | — | AUROC: 0.75 | — | Age, sex, father's ethnicity, mother ethnicity | Only unrelated individuals were considered in the analyses |
| PPM009232 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.77 | — | Age, sex, father's ethnicity, mother ethnicity | Only unrelated individuals were considered in the analyses |
| PPM009262 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.66 [1.25, 2.2] | AUROC: 0.548 | — | Age | — |
| PPM009264 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.57 [1.18, 2.08] | AUROC: 0.578 | — | Age, family history | — |
| PPM009261 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.66 [1.25, 2.19] | AUROC: 0.547 [0.52, 0.57] | — | — | — |
| PPM009263 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.56 [1.18, 2.08] | AUROC: 0.578 | — | Family history | — |
| PPM009265 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | — | AUROC: 0.6975 [0.673, 0.722] | Odds Ratio (OR, top 10% vs middle10%): 4.58 [2.88, 7.4] | Age at interview, menopausal status, age at menarche, age at first full-term pregnancy(1-4), parous, breast feeding, smoking status, body mass index, height, hormone-replacement therapy ever use, family history | — |
| PPM009332 | PGS001803 (portability-PLR_172) |
PSS008601| European Ancestry| 6,656 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0762 [0.0522, 0.1001] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009333 | PGS001803 (portability-PLR_172) |
PSS008379| Greater Middle Eastern Ancestry| 1,200 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0694 [0.0123, 0.1259] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009334 | PGS001803 (portability-PLR_172) |
PSS008155| South Asian Ancestry| 6,328 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0135 [-0.0382, 0.0112] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009330 | PGS001803 (portability-PLR_172) |
PSS009273| European Ancestry| 19,990 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.1136 [0.0999, 0.1272] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009331 | PGS001803 (portability-PLR_172) |
PSS009047| European Ancestry| 4,134 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0962 [0.0659, 0.1264] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009335 | PGS001803 (portability-PLR_172) |
PSS007943| East Asian Ancestry| 1,810 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0054 [-0.041, 0.0517] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009336 | PGS001803 (portability-PLR_172) |
PSS007725| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0065 [-0.046, 0.033] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009337 | PGS001803 (portability-PLR_172) |
PSS008827| African Ancestry| 3,924 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0165 [-0.0149, 0.0479] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009338 | PGS001804 (portability-PLR_174.1) |
PSS009274| European Ancestry| 10,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1101 [0.0908, 0.1292] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009339 | PGS001804 (portability-PLR_174.1) |
PSS009048| European Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0843 [0.0446, 0.1237] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009340 | PGS001804 (portability-PLR_174.1) |
PSS008602| European Ancestry| 3,484 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1125 [0.0795, 0.1453] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009343 | PGS001804 (portability-PLR_174.1) |
PSS007944| East Asian Ancestry| 1,143 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0983 [0.0401, 0.1559] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009344 | PGS001804 (portability-PLR_174.1) |
PSS007726| African Ancestry| 1,482 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0416 [-0.0097, 0.0927] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009345 | PGS001804 (portability-PLR_174.1) |
PSS008828| African Ancestry| 2,035 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0889 [0.0454, 0.132] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009341 | PGS001804 (portability-PLR_174.1) |
PSS008380| Greater Middle Eastern Ancestry| 467 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0772 [-0.0155, 0.1687] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009342 | PGS001804 (portability-PLR_174.1) |
PSS008156| South Asian Ancestry| 2,782 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0673 [0.0301, 0.1044] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009841 | PGS001869 (portability-PLR_681) |
PSS009345| European Ancestry| 19,807 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.0142 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009842 | PGS001869 (portability-PLR_681) |
PSS009119| European Ancestry| 4,093 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0247 [-0.0554, 0.006] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009843 | PGS001869 (portability-PLR_681) |
PSS008673| European Ancestry| 6,586 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.004 [-0.0282, 0.0201] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009844 | PGS001869 (portability-PLR_681) |
PSS008447| Greater Middle Eastern Ancestry| 1,189 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.0014 [-0.0559, 0.0587] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009845 | PGS001869 (portability-PLR_681) |
PSS008227| South Asian Ancestry| 6,213 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.0057 [-0.0192, 0.0306] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009846 | PGS001869 (portability-PLR_681) |
PSS008008| East Asian Ancestry| 1,803 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0207 [-0.0671, 0.0257] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009847 | PGS001869 (portability-PLR_681) |
PSS007792| African Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0078 [-0.0476, 0.0321] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009848 | PGS001869 (portability-PLR_681) |
PSS008896| African Ancestry| 3,853 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0033 [-0.0349, 0.0284] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009857 | PGS001871 (portability-PLR_696.4) |
PSS009347| European Ancestry| 19,615 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0636 [0.0497, 0.0775] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009858 | PGS001871 (portability-PLR_696.4) |
PSS009121| European Ancestry| 4,059 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.107 [0.0764, 0.1374] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009859 | PGS001871 (portability-PLR_696.4) |
PSS008675| European Ancestry| 6,554 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0404 [0.0162, 0.0646] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009860 | PGS001871 (portability-PLR_696.4) |
PSS008449| Greater Middle Eastern Ancestry| 1,183 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0463 [-0.0112, 0.1035] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009861 | PGS001871 (portability-PLR_696.4) |
PSS008229| South Asian Ancestry| 6,161 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0327 [0.0077, 0.0577] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009862 | PGS001871 (portability-PLR_696.4) |
PSS008010| East Asian Ancestry| 1,784 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0079 [-0.0388, 0.0545] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009863 | PGS001871 (portability-PLR_696.4) |
PSS007794| African Ancestry| 2,398 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0357 [-0.0045, 0.0757] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009864 | PGS001871 (portability-PLR_696.4) |
PSS008898| African Ancestry| 3,834 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): -0.0065 [-0.0382, 0.0252] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009865 | PGS001872 (portability-PLR_697) |
PSS009348| European Ancestry| 19,670 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0199 [0.0059, 0.0338] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009866 | PGS001872 (portability-PLR_697) |
PSS009122| European Ancestry| 4,059 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0123 [-0.0186, 0.0431] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009867 | PGS001872 (portability-PLR_697) |
PSS008676| European Ancestry| 6,565 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0166 [-0.0076, 0.0408] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009868 | PGS001872 (portability-PLR_697) |
PSS008450| Greater Middle Eastern Ancestry| 1,186 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0554 [-0.002, 0.1124] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009869 | PGS001872 (portability-PLR_697) |
PSS008230| South Asian Ancestry| 6,194 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.018 [-0.0069, 0.0429] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009871 | PGS001872 (portability-PLR_697) |
PSS008899| African Ancestry| 3,882 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0332 [0.0017, 0.0647] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009870 | PGS001872 (portability-PLR_697) |
PSS007795| African Ancestry| 2,441 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0157 [-0.0242, 0.0555] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009873 | PGS001873 (portability-PLR_704) |
PSS009124| European Ancestry| 4,120 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0826 [0.0521, 0.113] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009874 | PGS001873 (portability-PLR_704) |
PSS008678| European Ancestry| 6,645 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0472 [0.0232, 0.0712] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009876 | PGS001873 (portability-PLR_704) |
PSS008232| South Asian Ancestry| 6,308 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0395 [0.0147, 0.0641] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009877 | PGS001873 (portability-PLR_704) |
PSS008012| East Asian Ancestry| 1,809 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): -0.0177 [-0.064, 0.0287] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009878 | PGS001873 (portability-PLR_704) |
PSS007797| African Ancestry| 2,478 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): -0.0289 [-0.0684, 0.0106] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009879 | PGS001873 (portability-PLR_704) |
PSS008901| African Ancestry| 3,918 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): -0.0047 [-0.0361, 0.0267] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009872 | PGS001873 (portability-PLR_704) |
PSS009350| European Ancestry| 19,926 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.056 [0.0422, 0.0699] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009875 | PGS001873 (portability-PLR_704) |
PSS008452| Greater Middle Eastern Ancestry| 1,195 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0567 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009880 | PGS001874 (portability-PLR_706.2) |
PSS009351| European Ancestry| 19,952 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0461 [0.0323, 0.06] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009881 | PGS001874 (portability-PLR_706.2) |
PSS009125| European Ancestry| 4,124 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0709 [0.0404, 0.1013] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009882 | PGS001874 (portability-PLR_706.2) |
PSS008679| European Ancestry| 6,646 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0466 [0.0225, 0.0706] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009883 | PGS001874 (portability-PLR_706.2) |
PSS008453| Greater Middle Eastern Ancestry| 1,194 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0522 [-0.005, 0.1091] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009884 | PGS001874 (portability-PLR_706.2) |
PSS008233| South Asian Ancestry| 6,311 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.049 [0.0243, 0.0736] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009885 | PGS001874 (portability-PLR_706.2) |
PSS008013| East Asian Ancestry| 1,807 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): -0.0163 [-0.0627, 0.0301] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009886 | PGS001874 (portability-PLR_706.2) |
PSS007798| African Ancestry| 2,471 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): -0.0263 [-0.0659, 0.0133] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009887 | PGS001874 (portability-PLR_706.2) |
PSS008902| African Ancestry| 3,913 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): -0.01 [-0.0414, 0.0214] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010986 | PGS002014 (portability-ldpred2_172) |
PSS009273| European Ancestry| 19,990 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.1242 [0.1105, 0.1378] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010990 | PGS002014 (portability-ldpred2_172) |
PSS008155| South Asian Ancestry| 6,328 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0147 [-0.0394, 0.01] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010991 | PGS002014 (portability-ldpred2_172) |
PSS007943| East Asian Ancestry| 1,810 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0041 [-0.0504, 0.0423] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010992 | PGS002014 (portability-ldpred2_172) |
PSS007725| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0062 [-0.0457, 0.0333] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010993 | PGS002014 (portability-ldpred2_172) |
PSS008827| African Ancestry| 3,924 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0146 [-0.0168, 0.0459] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010987 | PGS002014 (portability-ldpred2_172) |
PSS009047| European Ancestry| 4,134 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0876 [0.0572, 0.1178] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010988 | PGS002014 (portability-ldpred2_172) |
PSS008601| European Ancestry| 6,656 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.076 [0.0521, 0.0999] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010989 | PGS002014 (portability-ldpred2_172) |
PSS008379| Greater Middle Eastern Ancestry| 1,200 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0717 [0.0147, 0.1282] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010994 | PGS002015 (portability-ldpred2_174.1) |
PSS009274| European Ancestry| 10,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1132 [0.094, 0.1324] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010995 | PGS002015 (portability-ldpred2_174.1) |
PSS009048| European Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0807 [0.041, 0.1201] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010996 | PGS002015 (portability-ldpred2_174.1) |
PSS008602| European Ancestry| 3,484 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1091 [0.076, 0.1419] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010997 | PGS002015 (portability-ldpred2_174.1) |
PSS008380| Greater Middle Eastern Ancestry| 467 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0976 [0.005, 0.1885] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010998 | PGS002015 (portability-ldpred2_174.1) |
PSS008156| South Asian Ancestry| 2,782 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0798 [0.0426, 0.1167] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010999 | PGS002015 (portability-ldpred2_174.1) |
PSS007944| East Asian Ancestry| 1,143 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1146 [0.0565, 0.1719] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011000 | PGS002015 (portability-ldpred2_174.1) |
PSS007726| African Ancestry| 1,482 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0482 [-0.0031, 0.0992] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011001 | PGS002015 (portability-ldpred2_174.1) |
PSS008828| African Ancestry| 2,035 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0842 [0.0407, 0.1274] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011509 | PGS002081 (portability-ldpred2_681) |
PSS009345| European Ancestry| 19,807 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.0247 [0.0108, 0.0386] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011510 | PGS002081 (portability-ldpred2_681) |
PSS009119| European Ancestry| 4,093 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.0189 [-0.0118, 0.0496] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011511 | PGS002081 (portability-ldpred2_681) |
PSS008673| European Ancestry| 6,586 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.009 [-0.0152, 0.0332] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011512 | PGS002081 (portability-ldpred2_681) |
PSS008447| Greater Middle Eastern Ancestry| 1,189 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.021 [-0.0364, 0.0782] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011513 | PGS002081 (portability-ldpred2_681) |
PSS008227| South Asian Ancestry| 6,213 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): 0.0082 [-0.0167, 0.0331] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011514 | PGS002081 (portability-ldpred2_681) |
PSS008008| East Asian Ancestry| 1,803 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0251 [-0.0715, 0.0213] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011516 | PGS002081 (portability-ldpred2_681) |
PSS008896| African Ancestry| 3,853 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0005 [-0.0321, 0.0312] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011515 | PGS002081 (portability-ldpred2_681) |
PSS007792| African Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Superficial cellulitis and abscess | — | — | Partial Correlation (partial-r): -0.0119 [-0.0518, 0.0279] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011525 | PGS002083 (portability-ldpred2_696.4) |
PSS009347| European Ancestry| 19,615 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0632 [0.0493, 0.0771] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011526 | PGS002083 (portability-ldpred2_696.4) |
PSS009121| European Ancestry| 4,059 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.1153 [0.0847, 0.1456] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011527 | PGS002083 (portability-ldpred2_696.4) |
PSS008675| European Ancestry| 6,554 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.041 [0.0168, 0.0652] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011529 | PGS002083 (portability-ldpred2_696.4) |
PSS008229| South Asian Ancestry| 6,161 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.03 [0.005, 0.055] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011530 | PGS002083 (portability-ldpred2_696.4) |
PSS008010| East Asian Ancestry| 1,784 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0119 [-0.0348, 0.0585] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011531 | PGS002083 (portability-ldpred2_696.4) |
PSS007794| African Ancestry| 2,398 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0375 [-0.0027, 0.0776] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011532 | PGS002083 (portability-ldpred2_696.4) |
PSS008898| African Ancestry| 3,834 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): -0.0166 [-0.0483, 0.0152] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011528 | PGS002083 (portability-ldpred2_696.4) |
PSS008449| Greater Middle Eastern Ancestry| 1,183 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Psoriasis | — | — | Partial Correlation (partial-r): 0.0458 [-0.0117, 0.1031] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011533 | PGS002084 (portability-ldpred2_697) |
PSS009348| European Ancestry| 19,670 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0184 [0.0044, 0.0324] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011534 | PGS002084 (portability-ldpred2_697) |
PSS009122| European Ancestry| 4,059 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0038 [-0.0271, 0.0346] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011535 | PGS002084 (portability-ldpred2_697) |
PSS008676| European Ancestry| 6,565 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0103 [-0.0139, 0.0345] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011536 | PGS002084 (portability-ldpred2_697) |
PSS008450| Greater Middle Eastern Ancestry| 1,186 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0603 [0.0029, 0.1173] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011537 | PGS002084 (portability-ldpred2_697) |
PSS008230| South Asian Ancestry| 6,194 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0182 [-0.0067, 0.0432] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011538 | PGS002084 (portability-ldpred2_697) |
PSS007795| African Ancestry| 2,441 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0131 [-0.0268, 0.0529] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011539 | PGS002084 (portability-ldpred2_697) |
PSS008899| African Ancestry| 3,882 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sarcoidosis | — | — | Partial Correlation (partial-r): 0.0187 [-0.0128, 0.0502] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011540 | PGS002085 (portability-ldpred2_702.2) |
PSS009349| European Ancestry| 19,837 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): 0.0237 [0.0098, 0.0376] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011541 | PGS002085 (portability-ldpred2_702.2) |
PSS009123| European Ancestry| 4,111 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): 0.03 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011542 | PGS002085 (portability-ldpred2_702.2) |
PSS008677| European Ancestry| 6,626 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): 0.0128 [-0.0113, 0.0369] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011543 | PGS002085 (portability-ldpred2_702.2) |
PSS008451| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): 0.0512 [-0.006, 0.108] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011544 | PGS002085 (portability-ldpred2_702.2) |
PSS008231| South Asian Ancestry| 6,321 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): -0.0097 [-0.0344, 0.015] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011545 | PGS002085 (portability-ldpred2_702.2) |
PSS008011| East Asian Ancestry| 1,807 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): -0.0149 [-0.0612, 0.0315] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011546 | PGS002085 (portability-ldpred2_702.2) |
PSS007796| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): 0.0158 [-0.0237, 0.0553] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011547 | PGS002085 (portability-ldpred2_702.2) |
PSS008900| African Ancestry| 3,922 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Seborrheic keratosis | — | — | Partial Correlation (partial-r): -0.0283 [-0.0596, 0.0031] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011549 | PGS002086 (portability-ldpred2_704) |
PSS009124| European Ancestry| 4,120 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0931 [0.0627, 0.1234] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011550 | PGS002086 (portability-ldpred2_704) |
PSS008678| European Ancestry| 6,645 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0507 [0.0267, 0.0747] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011551 | PGS002086 (portability-ldpred2_704) |
PSS008452| Greater Middle Eastern Ancestry| 1,195 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0436 [-0.0136, 0.1005] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011552 | PGS002086 (portability-ldpred2_704) |
PSS008232| South Asian Ancestry| 6,308 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0386 [0.0139, 0.0633] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011553 | PGS002086 (portability-ldpred2_704) |
PSS008012| East Asian Ancestry| 1,809 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): -0.0205 [-0.0668, 0.0258] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011554 | PGS002086 (portability-ldpred2_704) |
PSS007797| African Ancestry| 2,478 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): -0.0452 [-0.0846, -0.0057] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011555 | PGS002086 (portability-ldpred2_704) |
PSS008901| African Ancestry| 3,918 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.003 [-0.0284, 0.0344] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011548 | PGS002086 (portability-ldpred2_704) |
PSS009350| European Ancestry| 19,926 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Diseases of hair and hair follicles | — | — | Partial Correlation (partial-r): 0.0632 [0.0494, 0.0771] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011556 | PGS002087 (portability-ldpred2_706.2) |
PSS009351| European Ancestry| 19,952 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0513 [0.0374, 0.0651] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011557 | PGS002087 (portability-ldpred2_706.2) |
PSS009125| European Ancestry| 4,124 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0734 [0.0429, 0.1037] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011558 | PGS002087 (portability-ldpred2_706.2) |
PSS008679| European Ancestry| 6,646 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0454 [0.0214, 0.0694] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011559 | PGS002087 (portability-ldpred2_706.2) |
PSS008453| Greater Middle Eastern Ancestry| 1,194 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0444 [-0.0128, 0.1014] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011560 | PGS002087 (portability-ldpred2_706.2) |
PSS008233| South Asian Ancestry| 6,311 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0351 [0.0103, 0.0597] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011561 | PGS002087 (portability-ldpred2_706.2) |
PSS008013| East Asian Ancestry| 1,807 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): -0.0299 [-0.0762, 0.0165] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011562 | PGS002087 (portability-ldpred2_706.2) |
PSS007798| African Ancestry| 2,471 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): -0.0274 [-0.067, 0.0122] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011563 | PGS002087 (portability-ldpred2_706.2) |
PSS008902| African Ancestry| 3,913 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sebaceous cyst | — | — | Partial Correlation (partial-r): 0.0023 [-0.0291, 0.0338] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012734 | PGS002242 (ldpred_breastcancer) |
PSS009523| European Ancestry| 258,402 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.48 [1.45, 1.51] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012738 | PGS002242 (ldpred_breastcancer) |
PSS009519| European Ancestry| 110,597 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.45 [1.37, 1.53] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012742 | PGS002242 (ldpred_breastcancer) |
PSS009515| East Asian Ancestry| 178,726 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.25 [1.21, 1.28] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012746 | PGS002242 (ldpred_breastcancer) |
PSS009527| European Ancestry| 69,422 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.5 [1.43, 1.58] | — | — | birth year, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012750 | PGS002242 (ldpred_breastcancer) |
PSS009535| European Ancestry| 25,696 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.45 [1.38, 1.54] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012754 | PGS002242 (ldpred_breastcancer) |
PSS009531| African Ancestry| 1,535 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 0.9 [0.69, 1.17] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012758 | PGS002242 (ldpred_breastcancer) |
PSS009543| European Ancestry| 343,676 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.5 [1.47, 1.53] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012763 | PGS002242 (ldpred_breastcancer) |
PSS009539| African Ancestry| 7,618 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.12 [0.93, 1.35] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012768 | PGS002242 (ldpred_breastcancer) |
PSS009547| South Asian Ancestry| 7,628 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.47 [1.23, 1.75] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM013020 | PGS002293 (PRS62_psoriasis) |
PSS009651| European Ancestry| 345,672 individuals |
PGP000323 | Shen M et al. J Am Acad Dermatol (2022) |
Reported Trait: Incident psoriasis | HR: 4.625 [2.92, 7.348] | — | Odds Ratio (OR, poor lifestyle and high genetic risk): 4.625 [2.92, 7.348] Population-attributable fraction of genetic risk: 0.13 [0.032, 0.218] |
Age, sex, education, Townsend Index, and region, relatedness, number of alleles included in the polygenic risk score, and first 20 principal components of ancestry | — |
| PPM013022 | PGS002294 (PRS111) |
PSS009652| East Asian Ancestry| 1,104 individuals |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.648 [0.613, 0.682] | — | Nongenetic risk score (body mass index, waist-to-hip ratio (WHR), benign breast disease, age at menarche, age at first live birth, family history of breast cancer) | — |
| PPM013021 | PGS002294 (PRS111) |
PSS009652| East Asian Ancestry| 1,104 individuals |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Reported Trait: Breast cancer | OR: 1.67 [1.46, 1.92] | AUROC: 0.639 [0.604, 0.674] | — | — | — |
| PPM013085 | PGS002320 (disease_DERMATOLOGY.BOLT-LMM) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0005 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013134 | PGS002320 (disease_DERMATOLOGY.BOLT-LMM) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013183 | PGS002320 (disease_DERMATOLOGY.BOLT-LMM) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0032 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013232 | PGS002320 (disease_DERMATOLOGY.BOLT-LMM) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013109 | PGS002344 (disease_PSORIASIS.BOLT-LMM) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013158 | PGS002344 (disease_PSORIASIS.BOLT-LMM) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013207 | PGS002344 (disease_PSORIASIS.BOLT-LMM) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.007 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013256 | PGS002344 (disease_PSORIASIS.BOLT-LMM) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0035 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013373 | PGS002392 (disease_DERMATOLOGY.P+T.0.0001) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013422 | PGS002392 (disease_DERMATOLOGY.P+T.0.0001) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013471 | PGS002392 (disease_DERMATOLOGY.P+T.0.0001) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013520 | PGS002392 (disease_DERMATOLOGY.P+T.0.0001) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013397 | PGS002416 (disease_PSORIASIS.P+T.0.0001) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0005 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013446 | PGS002416 (disease_PSORIASIS.P+T.0.0001) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013495 | PGS002416 (disease_PSORIASIS.P+T.0.0001) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013544 | PGS002416 (disease_PSORIASIS.P+T.0.0001) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013569 | PGS002441 (disease_DERMATOLOGY.P+T.0.001) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013618 | PGS002441 (disease_DERMATOLOGY.P+T.0.001) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013667 | PGS002441 (disease_DERMATOLOGY.P+T.0.001) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013716 | PGS002441 (disease_DERMATOLOGY.P+T.0.001) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013593 | PGS002465 (disease_PSORIASIS.P+T.0.001) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0003 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013642 | PGS002465 (disease_PSORIASIS.P+T.0.001) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013691 | PGS002465 (disease_PSORIASIS.P+T.0.001) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013740 | PGS002465 (disease_PSORIASIS.P+T.0.001) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013765 | PGS002490 (disease_DERMATOLOGY.P+T.0.01) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013814 | PGS002490 (disease_DERMATOLOGY.P+T.0.01) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013863 | PGS002490 (disease_DERMATOLOGY.P+T.0.01) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013912 | PGS002490 (disease_DERMATOLOGY.P+T.0.01) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013789 | PGS002514 (disease_PSORIASIS.P+T.0.01) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0003 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013838 | PGS002514 (disease_PSORIASIS.P+T.0.01) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013887 | PGS002514 (disease_PSORIASIS.P+T.0.01) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013936 | PGS002514 (disease_PSORIASIS.P+T.0.01) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013961 | PGS002539 (disease_DERMATOLOGY.P+T.1e-06) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014010 | PGS002539 (disease_DERMATOLOGY.P+T.1e-06) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0037 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014059 | PGS002539 (disease_DERMATOLOGY.P+T.1e-06) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014108 | PGS002539 (disease_DERMATOLOGY.P+T.1e-06) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM013985 | PGS002563 (disease_PSORIASIS.P+T.1e-06) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0004 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014034 | PGS002563 (disease_PSORIASIS.P+T.1e-06) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014083 | PGS002563 (disease_PSORIASIS.P+T.1e-06) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014132 | PGS002563 (disease_PSORIASIS.P+T.1e-06) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014157 | PGS002588 (disease_DERMATOLOGY.P+T.5e-08) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014206 | PGS002588 (disease_DERMATOLOGY.P+T.5e-08) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0022 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014255 | PGS002588 (disease_DERMATOLOGY.P+T.5e-08) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014304 | PGS002588 (disease_DERMATOLOGY.P+T.5e-08) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014181 | PGS002612 (disease_PSORIASIS.P+T.5e-08) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0007 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014230 | PGS002612 (disease_PSORIASIS.P+T.5e-08) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014279 | PGS002612 (disease_PSORIASIS.P+T.5e-08) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014328 | PGS002612 (disease_PSORIASIS.P+T.5e-08) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014353 | PGS002637 (disease_DERMATOLOGY.PolyFun-pred) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0005 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_DERMATOLOGY.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014402 | PGS002637 (disease_DERMATOLOGY.PolyFun-pred) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0009 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_DERMATOLOGY.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014451 | PGS002637 (disease_DERMATOLOGY.PolyFun-pred) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0032 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_DERMATOLOGY.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014500 | PGS002637 (disease_DERMATOLOGY.PolyFun-pred) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0011 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_DERMATOLOGY.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014377 | PGS002661 (disease_PSORIASIS.PolyFun-pred) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_PSORIASIS.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014426 | PGS002661 (disease_PSORIASIS.PolyFun-pred) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_PSORIASIS.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014475 | PGS002661 (disease_PSORIASIS.PolyFun-pred) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.007 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_PSORIASIS.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014524 | PGS002661 (disease_PSORIASIS.PolyFun-pred) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model when combined with BOLT-LMM vs. covariates alone): 0.0034 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | See disease_PSORIASIS.mixweights file at http://data.broadinstitute.org/alkesgroup/polypred_results for combination weights |
| PPM014598 | PGS002686 (disease_DERMATOLOGY.SBayesR) |
PSS009724| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014549 | PGS002686 (disease_DERMATOLOGY.SBayesR) |
PSS009723| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0011 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014647 | PGS002686 (disease_DERMATOLOGY.SBayesR) |
PSS009725| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0016 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014696 | PGS002686 (disease_DERMATOLOGY.SBayesR) |
PSS009726| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Dermatologic diseases | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014622 | PGS002710 (disease_PSORIASIS.SBayesR) |
PSS009820| East Asian Ancestry| 922 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014671 | PGS002710 (disease_PSORIASIS.SBayesR) |
PSS009821| European Ancestry| 43,505 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0014 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014720 | PGS002710 (disease_PSORIASIS.SBayesR) |
PSS009822| South Asian Ancestry| 8,098 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.002 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014573 | PGS002710 (disease_PSORIASIS.SBayesR) |
PSS009819| African Ancestry| 6,503 individuals |
PGP000332 | Weissbrod O et al. Nat Genet (2022) |
Reported Trait: Psoriasis | — | — | Incremental R2 (full model vs. covariates alone): 0.0001 | age, sex, age*sex, assessment center, genotyping array, 10 PCs | — |
| PPM014955 | PGS002755 (Atopic_dermatitis_prscs) |
PSS009939| European Ancestry| 39,444 individuals |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Reported Trait: Atopic dermatitis | OR: 1.28 [1.21, 1.34] | — | — | age, sex, 10 PCs, technical covariates | — |
| PPM020709 | PGS002755 (Atopic_dermatitis_prscs) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |Ext. |
Reported Trait: Incident atopic dermatitis | — | — | Hazard ratio (HR, high vs low PRS): 1.249 [1.123, 1.391] | sex, age, Townsend index, moderate physical and household income | — |
| PPM020710 | PGS002755 (Atopic_dermatitis_prscs) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |Ext. |
Reported Trait: Incident atopic dermatitis with air pollution level | — | — | Hazard ratio (HR, high air pollution and high PRS vs low air pollution and low PRS): 1.978 [1.624, 2.411] | sex, age, Townsend index, moderate physical and household income | — |
| PPM016255 | PGS003380 (best_BRCA) |
PSS010074| European Ancestry| 154,361 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: breast cancer | — | AUROC: 0.696 | R²: 0.0555 | age, top 20 genetic principal components | — |
| PPM016257 | PGS003382 (best_SKCM) |
PSS010085| European Ancestry| 273,786 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: skin cutaneous melanoma | — | AUROC: 0.682 | R²: 0.0261 | age, sex, top 20 genetic principal components | — |
| PPM016280 | PGS003396 (PRS-11ASN) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.35 [1.25, 1.45] | AUROC: 0.58 [0.56, 0.61] | — | principal component | — |
| PPM016281 | PGS003397 (PRS-42ASN) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.4 [1.3, 1.51] | AUROC: 0.6 [0.58, 0.62] | — | principal component | — |
| PPM016282 | PGS003398 (PRS-136EUR) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.55 [1.44, 1.66] | AUROC: 0.62 [0.6, 0.64] | — | principal component | — |
| PPM016283 | PGS003399 (PRS-209EUR) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.54 [1.43, 1.66] | AUROC: 0.62 [0.6, 0.64] | — | principal component | — |
| PPM017069 | PGS003416 (MTAGPRS) |
PSS010113| European Ancestry| 18,933 individuals |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Reported Trait: Keratinocyte cancers | OR: 1.66 [1.55, 1.79] | — | — | age, sex, 10 ancesty PCs | — |
| PPM017070 | PGS003417 (UKBPRS) |
PSS010113| European Ancestry| 18,933 individuals |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Reported Trait: Keratinocyte cancers | OR: 1.56 [1.45, 1.67] | — | — | age, sex, 10 ancesty PCs | — |
| PPM017414 | PGS003459 (PRS_CO) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 1.83 [1.17, 2.84] | AUROC: 0.585 | — | PCs 1-2 | — |
| PPM017412 | PGS003486 (PRS_AE) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 1.89 [1.08, 3.3] | AUROC: 0.567 | — | PCs 1-2 | — |
| PPM018494 | PGS003738 (PRS136_BC) |
PSS010985| European Ancestry| 738 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Breast cancer | OR: 1.4 [1.27, 1.54] | — | — | — | — |
| PPM018501 | PGS003745 (PRS57_SM) |
PSS010995| European Ancestry| 448 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Skin Melanoma | OR: 1.49 [1.34, 1.66] | — | — | — | — |
| PPM018544 | PGS003758 (BrCa_PRS_JPHC_JPGWAS) |
PSS011015| East Asian Ancestry| 8,001 individuals |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Reported Trait: Incident breast cancer | — | C-index: 0.598 (0.018) | Improvement in C-index from age-only model: 0.058 Hazard ratio (HR, high vs low tertile): 2.47 [1.64, 3.7] |
age | — |
| PPM018545 | PGS003759 (BrCa_PRS_JPHC_EURGWAS) |
PSS011015| East Asian Ancestry| 8,001 individuals |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Reported Trait: Incident breast cancer | — | C-index: 0.586 (0.018) | Improvement in C-index from age-only model: 0.046 Hazard ratio (HR, high vs low tertile): 2.25 [1.51, 3.33] |
age | — |
| PPM019389 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.60508 β: 0.47317 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019390 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.71525 β: 0.53956 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019391 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.53934 β: 0.43136 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019392 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.70143 β: 0.53147 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019394 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.75801 β: 0.56418 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019393 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.467 β: 0.38322 |
AUROC: 0.6 | — | 0 | beta = log(or)/sd_pgs |
| PPM019425 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.65454 β: 0.50352 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019426 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.7112 β: 0.5372 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019427 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.60371 β: 0.47232 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019428 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.71179 β: 0.53754 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019429 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.48538 β: 0.39567 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019430 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.75341 β: 0.56157 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019401 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.66191 β: 0.50797 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019402 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.77035 β: 0.57118 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019403 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.61352 β: 0.47842 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019404 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.74007 β: 0.55393 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019405 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.44836 β: 0.37043 |
AUROC: 0.6 | — | 0 | beta = log(or)/sd_pgs |
| PPM019406 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.80647 β: 0.59138 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019365 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.66024 β: 0.50696 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019366 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.77072 β: 0.57138 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019367 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.60503 β: 0.47314 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019368 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.74575 β: 0.55719 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019369 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.46589 β: 0.38246 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019370 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.80882 β: 0.59268 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019413 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.61464 β: 0.47911 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019414 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.72899 β: 0.54754 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019415 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.58283 β: 0.45922 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019416 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.7155 β: 0.5397 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019417 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.42423 β: 0.35363 |
AUROC: 0.6 | — | 0 | beta = log(or)/sd_pgs |
| PPM019418 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.75979 β: 0.5652 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019407 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.64103 β: 0.49532 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019408 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.7432 β: 0.55573 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019409 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.56536 β: 0.44811 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019410 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.72445 β: 0.54491 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019411 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.51041 β: 0.41238 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019412 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.78417 β: 0.57895 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019419 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.62802 β: 0.48736 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019420 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.73797 β: 0.55272 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019421 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.57454 β: 0.45396 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019422 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.72094 β: 0.54287 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019423 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.51133 β: 0.41299 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019424 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.77492 β: 0.57375 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019371 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.50345 β: 0.40776 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019372 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.5159 β: 0.41601 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019373 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.41368 β: 0.34619 |
AUROC: 0.6 | — | 0 | beta = log(or)/sd_pgs |
| PPM019374 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.51726 β: 0.4169 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019375 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.36644 β: 0.31221 |
AUROC: 0.59 | — | 0 | beta = log(or)/sd_pgs |
| PPM019376 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.52553 β: 0.42234 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019377 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.51371 β: 0.41457 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019378 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.57309 β: 0.45304 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019379 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.48885 β: 0.39801 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019380 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.54351 β: 0.43406 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019381 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.35605 β: 0.30458 |
AUROC: 0.59 | — | 0 | beta = log(or)/sd_pgs |
| PPM019382 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.58738 β: 0.46208 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019395 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.59437 β: 0.46648 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019396 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.66993 β: 0.51278 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019397 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.51618 β: 0.41619 |
AUROC: 0.61 | — | 0 | beta = log(or)/sd_pgs |
| PPM019398 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.73541 β: 0.55124 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019399 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.41849 β: 0.34959 |
AUROC: 0.6 | — | 0 | beta = log(or)/sd_pgs |
| PPM019400 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.75895 β: 0.56472 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019383 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.68728 β: 0.52312 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019384 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.79574 β: 0.58542 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019385 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.65971 β: 0.50664 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019386 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.77954 β: 0.57636 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019387 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.54652 β: 0.43601 |
AUROC: 0.62 | — | 0 | beta = log(or)/sd_pgs |
| PPM019388 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti M R et al. medRxiv (2023) |Pre |
Reported Trait: Breast cancer | OR: 1.82572 β: 0.60197 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM020099 | PGS004166 (bc_1) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64831 | — | year of birth | — |
| PPM020100 | PGS004167 (bc_2) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64213 | — | year of birth | — |
| PPM020101 | PGS004168 (bc_3) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64699 | — | year of birth | — |
| PPM020102 | PGS004169 (bc_4) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64504 | — | year of birth | — |
| PPM020103 | PGS004170 (bc_5) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64455 | — | year of birth | — |
| PPM020299 | PGS004242 (PRS306_breast) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Breast cancer | HR: 1.58 [1.53, 1.64] | — | — | first 10 genetic principal components | — |
| PPM020312 | PGS004247 (PRS65_melanoma) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Melanoma | HR: 1.71 [1.55, 1.89] | — | — | first 10 genetic principal components | — |
| PPM020304 | PGS004247 (PRS65_melanoma) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Melanoma | HR: 1.78 [1.62, 1.96] | — | — | first 10 genetic principal components | — |
| PPM020383 | PGS004315 (GRS-ALL) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Family history of psoriasis | OR: 1.02 [1.0, 1.04] | — | R²: 0.0067 | — | — |
| PPM020384 | PGS004315 (GRS-ALL) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Age of psoriasis onset | OR: 0.71 [0.59, 0.85] | — | R²: 0.023 | — | — |
| PPM020386 | PGS004315 (GRS-ALL) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Age of type1 psoriasis onset | OR: 0.82 [0.59, 0.85] | — | R²: 0.0206 | — | — |
| PPM020388 | PGS004315 (GRS-ALL) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Psoriasis severity | OR: 1.02 [1.0, 1.06] | — | R²: 0.061 | — | — |
| PPM020390 | PGS004315 (GRS-ALL) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Total number of locations ever affected by psoriasis | OR: 1.16 [1.11, 1.21] | — | R²: 0.061 | — | — |
| PPM020393 | PGS004315 (GRS-ALL) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Initial presentation of psoriasis at elbow or knee | OR: 0.97 [0.94, 0.99] | — | — | — | — |
| PPM020396 | PGS004315 (GRS-ALL) |
PSS011348| European Ancestry| 345 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Psoriasis in genital area | β: -0.037 (0.016) | — | — | — | — |
| PPM020385 | PGS004316 (GRS-HLA) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Age of psoriasis onset | OR: 0.46 [0.34, 0.63] | — | R²: 0.0398 | — | — |
| PPM020387 | PGS004316 (GRS-HLA) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Age of type1 psoriasis onset | OR: 0.69 [0.56, 0.86] | — | R²: 0.0216 | — | — |
| PPM020389 | PGS004316 (GRS-HLA) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Psoriasis severity | OR: 1.09 [1.03, 1.15] | — | R²: 0.077 | — | — |
| PPM020391 | PGS004316 (GRS-HLA) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Total number of locations ever affected by psoriasis | OR: 1.34 [1.24, 1.45] | — | R²: 0.077 | — | — |
| PPM020394 | PGS004316 (GRS-HLA) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Initial presentation of psoriasis at elbow or knee | OR: 0.92 [0.88, 0.96] | — | — | — | — |
| PPM020392 | PGS004317 (GRS-noHLA) |
PSS011349| European Ancestry| 654 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Psoriasis in genital area | OR: 0.97 [0.94, 1.0] | — | — | — | — |
| PPM020395 | PGS004317 (GRS-noHLA) |
PSS011348| European Ancestry| 345 individuals |
PGP000547 | Bui A et al. Front Genet (2023) |
Reported Trait: Psoriasis in genital area | β: -0.038 (0.019) | — | — | — | — |
| PPM020437 | PGS004324 (PRS6314_PN) |
PSS011361| European Ancestry| 405,582 individuals |
PGP000558 | Vasavda C et al. J Invest Dermatol (2023) |
Reported Trait: Prurigo nodularis | OR: 1.27 | — | — | race, age, and sex | — |
| PPM020556 | PGS004441 (disease.breast_cancer.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: Breast cancer | OR: 1.22014 | — | — | — | — |
| PPM020626 | PGS004511 (meta.breast_cancer.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: Breast cancer | OR: 1.22647 | — | — | — | — |
| PPM020694 | PGS004579 (BRCA_PRSCS) |
PSS011365| European Ancestry| 190,879 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Breast cancer | OR: 1.76 [1.73, 1.79] | — | — | — | — |
| PPM020707 | PGS004587 (PRS23_AD) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |
Reported Trait: Incident atopic dermatitis | — | — | Hazard ratio (HR, high vs low PRS): 1.153 [1.037, 1.282] | sex, age, Townsend index, moderate physical and household income | — |
| PPM020708 | PGS004587 (PRS23_AD) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |
Reported Trait: Incident atopic dermatitis with air pollution level | — | — | Hazard ratio (HR, high air pollution and high PRS vs low air pollution and low PRS): 1.523 [1.259, 1.84] | sex, age, Townsend index, moderate physical and household income | — |
| PPM020722 | PGS004592 (PRS_KC) |
PSS011383| European Ancestry| 998 individuals |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Reported Trait: Keratinocyte cancer | OR: 1.51 [1.3, 1.76] | AUROC: 0.74 | R²: 0.231 | Age, sex, self-reported skin tanning ability, clinical grade of neck elastosis, genotyping batch, first 2 PCs | — |
| PPM020723 | PGS004592 (PRS_KC) |
PSS011383| European Ancestry| 998 individuals |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Reported Trait: Keratinocyte cancer | — | — | Odds ratio (OR, top PRS quintile vs bottom PRS quintile): 3.45 [2.18, 5.5] | Age, sex, self-reported skin tanning ability, clinical grade of neck elastosis, genotyping batch, first 2 PCs | — |
| PPM020786 | PGS004611 (RORP_PRS) |
PSS011411| Multi-ancestry (including European)| 10,196 individuals |
PGP000590 | Shieh Y et al. NPJ Precis Oncol (2023) |
Reported Trait: Breast cancer-specific survival | HR: 1.13 [1.06, 1.21] | — | — | 10 PCs | — |
| PPM020873 | PGS004688 (breast_cancer) |
PSS011432| European Ancestry| 21,249 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.665 | — | — | — |
| PPM020962 | PGS004737 (breast_cancer_PRSmix_eur) |
PSS011486| European Ancestry| 5,680 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Breast cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.038 [0.028, 0.048] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM020963 | PGS004738 (breast_cancer_PRSmixPlus_eur) |
PSS011486| European Ancestry| 5,680 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Breast cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.038 [0.028, 0.048] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM021102 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 18.2 [9.36, 35.4] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
| PPM021103 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 3.19 [2.51, 4.05] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
| PPM021104 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 3.84 [3.12, 4.72] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
| PPM021105 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 5.67 [3.84, 8.38] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
| PPM021101 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 16.2 [8.1, 32.5] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
| PPM021113 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 15.04 [6.06, 37.34] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
| PPM021114 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 21.24 [9.84, 45.84] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
| PPM021115 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 4.17 [3.06, 5.68] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
| PPM021116 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 4.86 [3.71, 6.37] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
| PPM021117 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 6.51 [4.0, 10.6] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
| PPM021118 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BARD1 carriers younger than 40 years | OR: 1.94 [1.02, 3.68] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BARD1 variant carriers vs non-carriers |
| PPM021119 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRIP1 carriers younger than 40 years | OR: 2.73 [1.65, 4.54] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRIP1 variant carriers vs non-carriers |
| PPM021120 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CDH1 carriers younger than 40 years | OR: 17.98 [3.8, 85.06] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CDH1 variant carriers vs non-carriers |
| PPM021121 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among NF1 carriers younger than 40 years | OR: 2.34 [0.75, 7.31] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in NF1 variant carriers vs non-carriers |
| PPM021106 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 61.05 [25.31, 147.28] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
| PPM021107 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 13.16 [4.29, 35.2] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
| PPM021108 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 1.78 [0.92, 3.46] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
| PPM021109 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 1.79 [1.02, 3.14] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
| PPM021110 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 11.95 [6.41, 22.3] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
| PPM021111 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BARD1 carriers younger than 40 years | OR: 4.42 [1.9, 10.3] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BARD1 variant carriers vs non-carriers |
| PPM021112 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRIP1 carriers younger than 40 years | OR: 2.45 [1.0, 5.97] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRIP1 variant carriers vs non-carriers |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000001 | All breast cancer | — | [
|
— | European | — | 33 cohorts
|
iCOGS |
| PSS000002 | ER-negative breast cancer | — | [
|
— | European | — | 33 cohorts
|
iCOGS |
| PSS000003 | ER-positive breast cancer | — | [
|
— | European | — | 33 cohorts
|
iCOGS |
| PSS011432 | — | — | [
|
— | European | — | UKB | — |
| PSS000004 | Invasive breast cancer-affected | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS000005 | ER-positive breast cancer cases | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS000006 | ER-negative breast cancer cases | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS000007 | Incident registry-confirmed invasive breast cancers developed | — | [ ,
0.0 % Male samples |
— | European | — | UKB | Prospective Test Set (UKB) |
| PSS000014 | Breast cancer ascertainment was based on self-report in an interview with a trained nurse, ICD-9 codes (174 or 174.9) or ICD-10 codes (C50.X) in hospitalization records, or a breast cancer diagnosis reported to the national registry before the date of enrollment. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | UKB Phase 2 |
| PSS009273 | — | — | 19,990 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009274 | — | — | 10,197 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS000038 | Cases were ascertained by linkage to the California Cancer Registry and defined as pathologically-confirmed diagnoses of invasive breast cancers with positive/elevated ER expression on immunohistochemical staining. ER-negative cases and those with unavailable ER status were excluded. Excluded women self-identified as premenopausal, perimenopausal, or postmenopausal as a direct result of surgery or medical treatments, such as chemotherapy. Women on hormonal therapy or selective estrogen receptor modulators at the time of blood draw were also excluded. | — | [ ,
0.0 % Male samples |
— | East Asian | — | CPMCBHC | Nested case-control study from the CPMC Breast Health Cohort. |
| PSS000039 | Cases were ascertained by linkage to the California Cancer Registry and defined as pathologically-confirmed diagnoses of invasive breast cancers with positive/elevated ER expression on immunohistochemical staining. ER-negative cases and those with unavailable ER status were excluded. Excluded women self-identified as premenopausal, perimenopausal, or postmenopausal as a direct result of surgery or medical treatments, such as chemotherapy. Women on hormonal therapy or selective estrogen receptor modulators at the time of blood draw were also excluded. | — | [ ,
0.0 % Male samples |
— | European | — | CPMCBHC | Nested case-control study from the CPMC Breast Health Cohort. |
| PSS000040 | Cases were ascertained by linkage to the California Cancer Registry and defined as pathologically-confirmed diagnoses of invasive breast cancers with positive/elevated ER expression on immunohistochemical staining. ER-negative cases and those with unavailable ER status were excluded. Excluded women self-identified as premenopausal, perimenopausal, or postmenopausal as a direct result of surgery or medical treatments, such as chemotherapy. Women on hormonal therapy or selective estrogen receptor modulators at the time of blood draw were also excluded. | — | [ ,
0.0 % Male samples |
— | East Asian, European, Hispanic or Latin American | — | CPMCBHC | Nested case-control study from the CPMC Breast Health Cohort. |
| PSS011486 | — | — | 5,680 individuals | — | European | — | AllofUs | — |
| PSS009345 | — | — | 19,807 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009347 | — | — | 19,615 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009348 | — | — | 19,670 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009349 | — | — | 19,837 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009350 | — | — | 19,926 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009351 | — | — | 19,952 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS000070 | BRCA1 mutation carriers were followed until breast or ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last observation whichever occurred first. | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 40 |
| PSS000071 | BRCA2 mutation carriers were followed until breast or ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last observation whichever occurred first. | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 43 |
| PSS000546 | PheCode:172.2; ICD9CM:173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, V10.83; ICD10CM:C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9 | — | [
|
— | European | — | MGI | — |
| PSS000544 | PheCode:172.21; ICD9CM:173.01, 173.11, 173.21, 173.31, 173.41, 173.51, 173.61, 173.71, 173.81, 173.91; ICD10CM:C44.01, C44.111, C44.112, C44.119, C44.211, C44.212, C44.219, C44.310, C44.311, C44.319, C44.41, C44.510, C44.511, C44.519, C44.611, C44.612, C44.619, C44.711, C44.712, C44.719, C44.81, C44.91 | — | [
|
— | European | — | MGI | — |
| PSS000548 | PheCode:172; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, 173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, 232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9, V10.82, V10.83; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9, D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
| PSS000547 | PheCode:172.3; ICD9CM:232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9; ICD10CM:D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
| PSS000549 | PheCode:174.1; ICD9CM:174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233.0, V10.3; ICD10CM:C50, C50.0, C50.01, C50.011, C50.012, C50.019, C50.02, C50.021, C50.022, C50.029, C50.1, C50.11, C50.111, C50.112, C50.119, C50.12, C50.121, C50.122, C50.129, C50.2, C50.21, C50.211, C50.212, C50.219, C50.22, C50.221, C50.222, C50.229, C50.3, C50.31, C50.311, C50.312, C50.319, C50.32, C50.321, C50.322, C50.329, C50.4, C50.41, C50.411, C50.412, C50.419, C50.42, C50.421, C50.422, C50.429, C50.5, C50.51, C50.511, C50.512, C50.519, C50.52, C50.521, C50.522, C50.529, C50.6, C50.61, C50.611, C50.612, C50.619, C50.62, C50.621, C50.622, C50.629, C50.8, C50.81, C50.811, C50.812, C50.819, C50.82, C50.821, C50.822, C50.829, C50.9, C50.91, C50.911, C50.912, C50.919, C50.92, C50.921, C50.922, C50.929, D05, D05.0, D05.00, D05.01, D05.02, D05.1, D05.10, D05.11, D05.12, D05.8, D05.80, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92 | — | [
|
— | European | — | MGI | — |
| PSS000074 | Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000078 | — | — | [ ,
0.0 % Male samples |
— | East Asian | — | 11 cohorts
|
— |
| PSS000079 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | SGWAS | SGWAS (Stage 1). Smaller set of the larger test set from this study. |
| PSS000080 | Questionnaires were mailed to women biennially to collect information on breast cancer risk factors, including age at menarche, age at first birth, parity, family history of breast cancer, height, weight, physical activity, menopausal status, age at menopause, and HT use. Incident breast cancer cases up to 1 June 2010 were also identified through biennial questionnaires. Diagnoses were confirmed with the participants (or next of kin), and permission was obtained to collect relevant medical or pathology reports. Analysis was restricted to invasive breast cancer. | Mean = 26.54 years | [ ,
0.0 % Male samples |
Mean = 53.7 years Sd = 8.0 years Range = [34.0, 70.0] years |
European, NR | — | NHS, NHS2 | Performance metrics are reported for the "All women" results of Table 2 |
| PSS000081 | Questionnaires were mailed to women biennially to collect information on breast cancer risk factors, including age at menarche, age at first birth, parity, family history of breast cancer, height, weight, physical activity, menopausal status, age at menopause, and HT use. Incident breast cancer cases up to 1 June 2010 were also identified through biennial questionnaires. Diagnoses were confirmed with the participants (or next of kin), and permission was obtained to collect relevant medical or pathology reports. Analysis was restricted to invasive breast cancer. | Mean = 23.08 years | [ ,
0.0 % Male samples |
Mean = 53.7 years Sd = 8.0 years Range = [34.0, 70.0] years |
European, NR | — | NHS, NHS2 | Performance metrics are reported for the "All women" results of Table 3 |
| PSS000082 | A family-based cohort including 323 breast cancer cases and 262 unaffected relatives from 101 families. Unaffected relatives derived from 49 out of 101 families. | — | [ ,
0.0 % Male samples |
Mean (Cases) = 51.0 years Sd (Cases) = 11.0 years |
European | — | NR | — |
| PSS000568 | PheCode:172.21; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
| PSS000570 | PheCode:174.1; ICD9:233.0; ICD10:C50.0, C50.1, C50.2, C50.3, C50.4, C50.5, C50.6, C50.8, C50.9, D05.1, D05.7, D05.9, Z85.3 | — | [
|
— | European | — | UKB | — |
| PSS011529 | — | — | [ ,
0.0 % Male samples |
— | European | — | 11 cohorts
|
— |
| PSS011535 | Cases are individuals who were incident diagnosed with invasive breast cancer. | Mean = 10.0 years | [ ,
0.0 % Male samples |
— | Not reported | — | MMHS | — |
| PSS011536 | Cases are individuals who were diagnosed with invasive breast cancer. They were free from cancer at the beginning of the study. | Mean = 10.0 years | [ ,
0.0 % Male samples |
— | Not reported | — | NHS | — |
| PSS003581 | All individuals were BRCA1 carriers. BRCA1 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 28 cohorts
|
Additional controls were obtained from UCHICAGO |
| PSS003582 | All individuals were BRCA2 carriers. BRCA2 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 35 cohorts
|
Additional controls were obtained from UCHICAGO |
| PSS003595 | Cases were individuals with invasive breast cancer. Of the 585 cases, 475 were individuals with prevalent invasive breast cancer whilst 110 were individuals with incident invasive breast cancer. Incident invasive breast cancer was adjudicated by an expert panel using histopathology, metastasis imaging or other clinical evidence. Histopathology was available for 103 of the 110 individuals with incident invasive breast cancer. Of the 103 individuals, 74 had incident invasive estrogren receptor postivie/progesterone receptor positive breast cancer. Age at diagnosis of prevalent invasive breast cancer was self-reported as before or after 50 years. Of the 475 individuals with prevalent invasive breast cancer 60 had been diagnosed before the age of 50, whilst the remaining 415 had been diagnosed at age 50 or over. | Median = 4.7 years IQR = [3.65, 5.75] years |
[ ,
0.0 % Male samples |
Mean = 75.1 years | European | — | ASPREE | — |
| PSS003598 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 59.6 years Sd = 16.5 years |
African unspecified | — | eMERGE | — |
| PSS003599 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 66.1 years Sd = 17.7 years |
European | — | eMERGE | — |
| PSS007618 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS003600 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 59.9 years Sd = 19.4 years |
Hispanic or Latin American | — | eMERGE | — |
| PSS007616 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007617 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007621 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007622 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007623 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS009515 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Japanese) |
— | BBJ | — |
| PSS007624 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007625 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007619 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007620 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009519 | — | — | [ ,
0.0 % Male samples |
— | European (Estonian) |
— | EB | — |
| PSS009523 | — | — | [ ,
0.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS009527 | — | — | [ ,
0.0 % Male samples |
— | European | Norwegian | HUNT | — |
| PSS009531 | — | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | MGBB | — |
| PSS009535 | — | — | [ ,
0.0 % Male samples |
— | European | — | MGBB | — |
| PSS009539 | — | — | [ ,
0.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS007651 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007652 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007653 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007654 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007655 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009543 | — | — | [ ,
0.0 % Male samples |
— | European | British | UKB | — |
| PSS009547 | — | — | [ ,
0.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS007661 | For the CHILD Cohort Study, atopic dermatitis (AD) was from physician diagnosis at the one year follow-up. AD severity was defined as mild if there is a single site or no more than 2 sites, minor symptoms (little itching/rubbing), minor crusting and papules, not excoriated or oozing, not needing frequent medical attention; was defined as moderate if symptoms are neither mild nor severe or; was defined as severe if there are multiple sites, with extensive crusting or papules or excoriations or oozing or lichenification, sleep loss, needing frequent medical attention, and is a major concern to parents. In the SLSJ Cohort, atopic dermatitis was self-reported and considered as positive if past or present occurrence was reported. For children, cross validation was done using questionnaires filled by their parents. Moreover, validation in medical records of these self-reported phenotypes were done for a subset of the SLSJ Cohort (n = 217), giving 89% concordance. | — | [ ,
42.0 % Male samples |
Mean = 9.0 years Range = [0.0, 87.0] years |
European, South East Asian, East Asian, South Asian, African American or Afro-Caribbean, Native American, Greater Middle Eastern (Middle Eastern, North African or Persian), Hispanic or Latin American, Not reported | — | CHILD, SLSJ | Also used to evaluate the PRS_atopicDermatitis for other diseases of the atopic march: food allergy, allergic asthma and rhinitis. Only unrelated individuals were selected for analyses. |
| PSS007670 | Cases were individuals who had been diagnosed with breast cancer. | — | [ ,
0.0 % Male samples |
— | European (Greek-Cypriot) |
— | NR | Cases and controls were obtained from the MASTOS study. |
| PSS000111 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 26000 | — | [ ,
0.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS009592 | — | — | [ ,
0.0 % Male samples |
— | Not reported | — | TCGA | — |
| PSS009609 | — | — | [ ,
0.0 % Male samples |
Range = [0.0, 50.0] years | European | — | NHS2, UKB | GS |
| PSS009610 | — | — | [ ,
0.0 % Male samples |
Range = [50.0, 100.0] years | European | — | 9 cohorts
|
GS |
| PSS009611 | — | — | 302,425 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | MCCS | — |
| PSS009612 | — | — | 840,867 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | EPIC | — |
| PSS009613 | — | — | 408,679 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | EPIC | — |
| PSS009614 | — | — | 188,453 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | KARMA | — |
| PSS009615 | — | — | 1,401,091 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | EPIC, PROCAS, UKB | — |
| PSS009616 | — | — | 5,328,392 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | 7 cohorts
|
GS |
| PSS007725 | — | — | 2,483 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007726 | — | — | 1,482 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS000207 | PheCode 172 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
| PSS000209 | Basal cell carcinoma: ICD9-173.01,173.11,173.21,173.31,173.41,173.51,173.61,173.71,173.81,173.91 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
| PSS000211 | PheCode 172 | — | [ ,
45.9 % Male samples |
Mean = 57.7 years Sd = 8.1 years |
European | White British Subset | UKB | — |
| PSS007792 | — | — | 2,440 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007794 | — | — | 2,398 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007795 | — | — | 2,441 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007796 | — | — | 2,483 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007797 | — | — | 2,478 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007798 | — | — | 2,471 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS000218 | Phenotypic information was self-reported by the individual through an online, interactive health history tool | — | [ ,
0.0 % Male samples |
— | European | — | CG | Samples are individuals whose healthcare provider had ordered a Color Genomics multi-gene panel test |
| PSS009651 | — | Median = 10.88 years | 345,672 individuals, 48.0 % Male samples |
Mean = 56.53 years Sd = 8.06 years |
European | — | UKB | — |
| PSS000854 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Breast cancer=(ICD-9 = 174 or ICD-10 = C50). | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS009652 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | NR | — |
| PSS000871 | Basal cell carcinoma cases were determined by a baseline survey containing 34 questions regarding personal history of skin cancer(including skin cancer type, age at diagnosis, body location, prescribed treatments and information regarding cancer recurrence) | — | [ ,
38.9 % Male samples |
European | — | 23andMe | — | |
| PSS000907 | Cases are individuals with vitiligo. Diagnoses of vitiligo in multiplex-affected subjects and reportedly unaffected family members were verified by manual review of all available phenotype information for each subject. | — | [
|
— | European | — | NR | — |
| PSS007943 | — | — | 1,810 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS007944 | — | — | 1,143 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS010968 | — | — | [
|
— | European | — | NR | GCAT |
| PSS010969 | — | — | [
|
— | European | — | NR | GCAT |
| PSS010974 | — | — | [
|
— | European | — | NR | GCAT |
| PSS010977 | — | — | 4,987 individuals | — | European | — | NR | GCAT |
| PSS010980 | — | — | 4,797 individuals | — | European | — | NR | GCAT |
| PSS009723 | — | — | 6,503 individuals | — | African unspecified | — | UKB | — |
| PSS009724 | — | — | 922 individuals | — | East Asian | — | UKB | — |
| PSS009725 | — | — | 43,505 individuals | — | European | Non-British European | UKB | — |
| PSS009726 | — | — | 8,098 individuals | — | South Asian | — | UKB | — |
| PSS008008 | — | — | 1,803 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS008010 | — | — | 1,784 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS008011 | — | — | 1,807 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS008012 | — | — | 1,809 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS008013 | — | — | 1,807 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS010985 | — | — | 738 individuals | Mean = 59.35 years | European | — | TCGA | — |
| PSS010995 | — | — | 448 individuals | Mean = 58.23 years | European | — | TCGA | — |
| PSS000970 | — | Median = 400.0 days | 1,584 individuals | — | European | — | GNEHGI2020Q2 | — |
| PSS011015 | — | Median = 16.9 years | [ ,
0.0 % Male samples |
Mean = 53.8 years Sd = 7.8 years |
East Asian (Japanese) |
— | JPHC | — |
| PSS000974 | Cases are individuals with breast cancer. 1380 of these are male breast cancer cases and 1671 are female breast cancer cases | — | [ ,
48.07 % Male samples |
— | European | — | B58C, COH, UK-BCN-MBCS, UKBGS | Additional male breast cancer cases were recruited from the University of Leeds, the University of Cambridge. |
| PSS009819 | — | — | 6,503 individuals | — | African unspecified | — | UKB | — |
| PSS009820 | — | — | 922 individuals | — | East Asian | — | UKB | — |
| PSS009821 | — | — | 43,505 individuals | — | European | Non-British European | UKB | — |
| PSS009822 | — | — | 8,098 individuals | — | South Asian | — | UKB | — |
| PSS000273 | Primary tumor samples from TCGA | — | [ ,
0.0 % Male samples |
Mean = 60.0 years Sd = 13.0 years |
European | — | TCGA | — |
| PSS000273 | — | — | [ ,
0.0 % Male samples |
— | European | — | eMERGE | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | European | — | CG | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | African unspecified | — | CG | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | CG | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | Not reported | — | CG | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | UKB | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | Not reported | — | UKB | — |
| PSS000982 | Cases were individuals with cutaneous melanoma. Of the 628 cases, 528 were prevalent melanoma, whilst 98 were incident melanoma cases. Endpoints used were primary invasive cutaneous melanoma and metastatic melanoma with unknown primary location occurring during the trial (incident). Metastatic recurrence was excluded. Incident melanomas were confirmed by expert panel using histopathology, imaging of metastasis or other clinical evidence. If a participant had two events during the trial, the time of the first event was used. Prevalent melanomas occurring pre-trial were self-reported by participants but not confirmed by review of medical records and assumed to be invasive. Age at diagnosis for self-reported melanomas was reported as either before or after 50 years. | Median = 4.7 years | [ ,
45.0 % Male samples |
Mean = 75.0 years Sd = 4.23 years |
European | — | ASPREE | — |
| PSS004153 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004154 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004155 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004156 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004157 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS004158 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004159 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004160 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004161 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004162 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS004168 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004169 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004170 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004171 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004172 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS004173 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004174 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004175 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004176 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004177 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS004178 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004179 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004180 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004181 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004182 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS008155 | — | — | 6,328 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008156 | — | — | 2,782 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS011069 | — | — | 495 individuals, 0.0 % Male samples |
Median = 53.0 years IQR = [48.0, 59.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS000995 | Cases are women with breast cancer. Of the 4414 breast cancer cases, 2470 were ER-positive and 1372 were ER-negative. | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | 10 cohorts
|
All cohorts part of African American Breast Cancer (AABC) consortium and/or The African American Breast Cancer Epidemiology and Risk (AMBER)consortium. |
| PSS000995 | Cases are women with breast cancer. Of the 3928 breast cancer cases, 1533 were ER-positive and 987 were ER-negative. | — | [ ,
0.0 % Male samples |
Mean = 47.71 years | African American or Afro-Caribbean, Sub-Saharan African, African unspecified | — | 15 cohorts
|
All cohorts part of The GAME-ON OncoArray Consortium or The GWAS of Breast Cancer in the African Diaspora Consortium (ROOT) |
| PSS000995 | Cases are women with breast cancer. Of the 899 breast cancer cases, 296 were ER-positive and 277 were ER-negative. | — | [ ,
0.0 % Male samples |
— | Sub-Saharan African | — | GBHS | — |
| PSS008227 | — | — | 6,213 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008229 | — | — | 6,161 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008230 | — | — | 6,194 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008231 | — | — | 6,321 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008232 | — | — | 6,308 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008233 | — | — | 6,311 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS009919 | — | — | 2,559 individuals, 0.0 % Male samples |
Mean = 54.0 years Sd = 8.4 years |
Not reported | — | NR | AMDTSS |
| PSS009925 | — | — | 295 individuals, 0.0 % Male samples |
— | Not reported | — | IARC | — |
| PSS009939 | — | — | 39,444 individuals | — | European (Finnish) |
— | FinnGen | — |
| PSS004384 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004385 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004386 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004387 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004388 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS001011 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS008379 | — | — | 1,200 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008380 | — | — | 467 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS000359 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (4) HER2-enriched-like (ER- and PR-, HER2+) | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000360 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (1) luminal A-like (ER+ and/or PR+, HER2-, grade 1 & 2); | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000361 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (2) luminal B/HER2-negative-like (ER+ and/or PR+, HER2-, grade 3) | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000362 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (3) luminal B-like (ER+ and/or PR+, HER2+); | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000363 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (5) triple-negative ( ER-, PR-, HER2-). | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS009971 | — | — | 30,716 individuals | — | European | — | MGBB | — |
| PSS009971 | — | — | 1,807 individuals | — | African unspecified (Black) |
— | MGBB | — |
| PSS009971 | — | — | 786 individuals | — | Asian unspecified | — | MGBB | — |
| PSS009971 | — | — | 3,113 individuals | — | Other | — | MGBB | — |
| PSS004471 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004472 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004473 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004474 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004475 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS008450 | — | — | 1,186 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008452 | — | — | 1,195 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008453 | — | — | 1,194 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008449 | — | — | 1,183 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008447 | — | — | 1,189 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008451 | — | — | 1,197 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS001054 | All women carried monoallelic protein-truncating germline variants (PTVs) in the CHEK2 gene. 557 of these were the c.1100delc mutation. Cases show individuals with breast cancer. | — | [ ,
0.0 % Male samples |
— | European | — | GC-HBOC | — |
| PSS004516 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004517 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004518 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004519 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS009990 | — | — | 207,510 individuals, 0.0 % Male samples |
— | European, Asian unspecified | European and Asian | 20 cohorts
|
BOSOM, NKR, UBCS |
| PSS004521 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004522 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004523 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004524 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004525 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS004520 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS008601 | — | — | 6,656 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS008602 | — | — | 3,484 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS000406 | Women with invasive breast cancer were considered cases and those without breast cancer were considered controls. | — | [ ,
0.0 % Male samples |
Mean (Age At Diagnosis, Cases) = 57.0 years Sd (Age At Diagnosis, Cases) = 13.0 years |
Hispanic or Latin American | — | 7 cohorts
|
See supplement for cohort-specific participant recruitment/ascertainment |
| PSS000407 | Women with invasive breast cancer were considered cases and those without breast cancer were considered controls. | — | [ ,
0.0 % Male samples |
— | Hispanic or Latin American | — | CAMA, COLUMBUS, PEGEN-BC | See supplement for cohort-specific participant recruitment/ascertainment |
| PSS000408 | Women with invasive breast cancer were considered cases and those without breast cancer were considered controls. | — | [ ,
0.0 % Male samples |
— | Hispanic or Latin American | — | MEC, NC-BCFR, RPEGH, SFBCS | See supplement for cohort-specific participant recruitment/ascertainment |
| PSS001105 | Breast cancer diagnosis (invasive or ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER+ subtype | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001108 | Breast cancer diagnosis (invasive or ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER- subtype. | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001107 | Breast cancer diagnosis (invasive) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER+ subtype | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001106 | Breast cancer diagnosis (ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER+ subtype | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001111 | Breast cancer diagnosis (invasive or ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems | — | [ ,
0.0 % Male samples |
Median = 60.0 years | Not reported | — | PROCAS | — |
| PSS001112 | Breast cancer diagnosis (ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001113 | Breast cancer diagnosis (invasive) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001110 | Breast cancer diagnosis (invasive) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER- subtype. | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS001109 | Breast cancer diagnosis (ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER- subtype. | — | [ ,
0.0 % Male samples |
— | Not reported | — | PROCAS | — |
| PSS008673 | — | — | 6,586 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS008675 | — | — | 6,554 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS008676 | — | — | 6,565 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS008677 | — | — | 6,626 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS008678 | — | — | 6,645 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS008679 | — | — | 6,646 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS011215 | — | — | [ ,
0.0 % Male samples |
— | European | — | EB | — |
| PSS011227 | C3_BREAST, ICD10: C0, ICD9: 174 | — | [ ,
0.0 % Male samples |
— | European | — | FinnGen | — |
| PSS011238 | — | — | [ ,
0.0 % Male samples |
— | South Asian | — | G&H | — |
| PSS011254 | — | — | [ ,
0.0 % Male samples |
— | European | — | HUNT | — |
| PSS000443 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
0.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS000444 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [
|
— | European (Finnish) |
— | FinnGen | — |
| PSS011268 | — | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS000450 | Breast cancer cases were identified through the Finnish Cancer Registry with diagnosis C50 (International Classification of Diseases for Oncology, 3rd Edition; ICD-O-3), from the drug reimbursement registry by selecting individuals with a reimbursement code for breast cancer, and from the death registry with ICD-10 C50. | — | [ ,
0.0 % Male samples |
Mean Age (At The End Of Follow-Up) = 58.5 years IQR = [45.1, 72.2] years |
European (Finnish) |
— | FinnGen | — |
| PSS011282 | — | — | [ ,
0.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS000463 | Unaffected family members from families with increased melaona risk. Recruited families were ranked as low-, medium- or high-risk using a risk index (T) that factored in the number of confirmed cases of melanoma versus number of unaffected family members, ages and year of birth | — | [ ,
46.28 % Male samples |
— | European | Australia | BATS, QFMP | — |
| PSS000464 | Unaffected family members from families with increased melaona risk. Recruited families were ranked as low-, medium- or high-risk using a risk index (T) that factored in the number of confirmed cases of melanoma versus number of unaffected family members, ages and year of birth | — | [ ,
46.37 % Male samples |
— | European | Australia | BATS, QFMP | — |
| PSS011296 | 22,667 sibling pairs | — | 45,334 individuals | — | European | — | UKB | — |
| PSS008827 | — | — | 3,924 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS008828 | — | — | 2,035 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS000480 | Women (European Ancestry) diagnosed with unilateral breast cancer | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | 8 cohorts
|
— |
| PSS000481 | Women (Asian Ancestry) diagnosed with unilateral breast cancer or CBC. CBC was defined as breast cancer (in situ or invasive) in the contralateral breast irrespective of the time since the first breast cancer. | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | 8 cohorts
|
— |
| PSS000482 | Women (European Ancestry) diagnosed with unilateral breast cancer or CBC. CBC was defined as breast cancer (in situ or invasive) in the contralateral breast irrespective of the time since the first breast cancer. | — | [ ,
0.0 % Male samples |
— | European | — | 63 cohorts
|
— |
| PSS000483 | Women (European Ancestry) diagnosed with unilateral breast cancer | — | [ ,
0.0 % Male samples |
— | European | — | 63 cohorts
|
— |
| PSS000484 | Women (European Ancestry) diagnosed with unilateral breast cancer or metachronous contralateral breast cancer (CBC). Metachronous contralateral breast cancer was defined as breast cancer in the contralateral breast (in situ or invasive) diagnosed at least 3 months after the first breast cancer. | Median = 8.4 years | [ ,
0.0 % Male samples |
Median (Age At Diagnosis) = 56.0 years | European | — | 42 cohorts
|
— |
| PSS000485 | Women (European Ancestry) diagnosed with unilateral breast cancer or metachronous contralateral breast cancer (CBC). Metachronous contralateral breast cancer was defined as breast cancer in the contralateral breast (in situ or invasive) diagnosed at least 3 months after the first breast cancer. | Median = 8.4 years | [ ,
0.0 % Male samples |
Median (Age At Diagnosis) = 56.0 years | European | — | 42 cohorts
|
— |
| PSS000486 | Women (European Ancestry) diagnosed with unilateral breast cancer or metachronous contralateral breast cancer (CBC). Metachronous contralateral breast cancer was defined as breast cancer in the contralateral breast (in situ or invasive) diagnosed at least 3 months after the first breast cancer. | Median = 8.4 years | [ ,
0.0 % Male samples |
Median (Age At Diagnosis) = 56.0 years | European | — | 42 cohorts
|
— |
| PSS010074 | C50 | — | [
|
— | European (British) |
— | UKB | Controls were samples without any cancer diagnosis or self-reported cancer |
| PSS000489 | The diagnosttic criteria for each disease was based on gold-standard clinical guidelines. | — | 339 individuals | — | European (Spanish) |
— | PRECISESADS | — |
| PSS004876 | — | — | 5,650 individuals | — | African unspecified | — | UKB | — |
| PSS004877 | — | — | 1,297 individuals | — | East Asian | — | UKB | — |
| PSS004878 | — | — | 19,358 individuals | — | European | non-white British ancestry | UKB | — |
| PSS004879 | — | — | 6,219 individuals | — | South Asian | — | UKB | — |
| PSS004880 | — | — | 50,754 individuals | — | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS010085 | C43 | — | [
|
— | European (British) |
— | UKB | Controls were samples without any cancer diagnosis or self-reported cancer |
| PSS000491 | — | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | 10 cohorts
|
— |
| PSS000492 | — | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | 10 cohorts
|
— |
| PSS000493 | — | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | 10 cohorts
|
— |
| PSS000494 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | MYBRCA, SGBCC | — |
| PSS000494 | — | — | [ ,
0.0 % Male samples |
— | South East Asian (Malay) |
— | MYBRCA, SGBCC | — |
| PSS000494 | — | — | [ ,
0.0 % Male samples |
— | South Asian (Indian) |
— | MYBRCA, SGBCC | — |
| PSS000495 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | MYBRCA, SGBCC | — |
| PSS000495 | — | — | [ ,
0.0 % Male samples |
— | South East Asian (Malay) |
— | MYBRCA, SGBCC | — |
| PSS010095 | — | — | 41,031 individuals, 0.0 % Male samples |
— | East Asian (Korean) |
— | KCPS | KPCS-II |
| PSS000495 | — | — | [ ,
0.0 % Male samples |
— | South Asian (Indian) |
— | MYBRCA, SGBCC | — |
| PSS000496 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | MYBRCA, SGBCC | — |
| PSS000496 | — | — | [ ,
0.0 % Male samples |
— | South East Asian (Malay) |
— | MYBRCA, SGBCC | — |
| PSS000496 | — | — | [ ,
0.0 % Male samples |
— | South Asian (Indian) |
— | MYBRCA, SGBCC | — |
| PSS000497 | — | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | CanBCS, LAABC, NC-BCFR | — |
| PSS000498 | — | — | [
|
— | Asian unspecified | — | CanBCS, LAABC, NC-BCFR | — |
| PSS000500 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | SCHS | — |
| PSS000499 | — | — | [
|
— | Asian unspecified | — | CanBCS, LAABC, NC-BCFR | — |
| PSS011321 | — | — | 10,717 individuals, 0.0 % Male samples |
— | African American or Afro-Caribbean (non-Hispanic African) |
— | MVP | Full combined ancestry cohort: median age = 49 years, median follow-up time = 3.9 years |
| PSS011322 | — | — | 19,939 individuals, 0.0 % Male samples |
— | European | — | MVP | Full combined ancestry cohort: median age = 49 years, median follow-up time = 3.9 years |
| PSS008896 | — | — | 3,853 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS008898 | — | — | 3,834 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS008899 | — | — | 3,882 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS008900 | — | — | 3,922 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS008901 | — | — | 3,918 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS008902 | — | — | 3,913 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS011328 | — | — | 133,830 individuals, 0.0 % Male samples |
— | European (British) |
— | UKB | — |
| PSS011329 | — | — | 115,207 individuals, 100.0 % Male samples |
— | European (British) |
— | UKB | — |
| PSS010113 | — | — | 18,933 individuals | — | European | — | CLSA | — |
| PSS000521 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
| PSS000522 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
| PSS000523 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
| PSS011349 | — | — | 654 individuals, 48.0 % Male samples |
Mean = 41.0 years Sd = 14.0 years |
European | — | NR | — |
| PSS000525 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
| PSS000526 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
| PSS000527 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
| PSS011348 | — | — | 345 individuals, 52.0 % Male samples |
Mean = 49.0 years Sd = 16.0 years |
European | — | UCSF | — |
| PSS000529 | Eligibility was restricted to female BRCA1 and BRCA2 carriers who at completion of the baseline questionnaire were free of any cancer diagnosis (excluding non-melanoma skin cancer) and had not undergone risk-reducing bilateral mastectomy. Participants diagosed with a first breast cancer were considered affected. | — | [ ,
0.0 % Male samples |
— | European | — | 61 cohorts
|
— |
| PSS000531 | Eligibility was restricted to female BRCA1 and BRCA2 carriers who at completion of the baseline questionnaire were free of any cancer diagnosis (excluding non-melanoma skin cancer) and had not undergone risk-reducing bilateral mastectomy. Participants diagosed with a first breast cancer were considered affected. | — | [ ,
0.0 % Male samples |
— | European | — | 61 cohorts
|
— |
| PSS011356 | — | — | 17,835 individuals, 0.0 % Male samples |
— | European | — | KARMA | — |
| PSS010142 | — | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS011361 | — | — | [
|
— | European | — | UKB | — |
| PSS011364 | — | — | 56,192 individuals | — | European | — | UKB | — |
| PSS011365 | — | — | [ ,
0.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS011376 | — | Median = 12.0 years | 337,910 individuals, 45.6 % Male samples |
Mean = 57.1 years Sd = 8.0 years |
European | — | UKB | — |
| PSS011383 | — | — | [ ,
44.0 % Male samples |
— | European | — | NSCS | — |
| PSS011384 | — | — | 12,920 individuals, 0.0 % Male samples |
Mean = 50.9 years Sd = 11.1 years |
Asian unspecified | — | BCAC | — |
| PSS011385 | — | — | 683 individuals, 0.0 % Male samples |
Mean = 54.4 years Sd = 9.2 years |
European | — | MINDACT | — |
| PSS009047 | — | — | 4,134 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009048 | — | — | 2,440 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS010184 | — | — | [ ,
0.0 % Male samples |
Range = [40.0, 69.0] years | European | — | UKB | — |
| PSS011411 | — | — | 10,196 individuals, 0.0 % Male samples |
— | European, Not reported | — | Pathways, UKB | — |
| PSS010186 | Plaque psoriasis patients with at least one exposure to biologic therapy. Cases developed one or more paradoxical eczema adverse events during treatment with one of the following biologics: TNF-alpha inhibitors (adalimumab; etanercept; certolizumab; infliximab), IL-17 inhibitors (brodalumab; secukinumab; ixekizumab), IL-12/23 inhibitors (ustekinumab) and IL-23p19 inhibitors (guselkumab; risankizumab; tildrakizumab). Controls has no recorded eczema events during biologic therapy. Participants may have been exposed to more than one biologic. | — | [
|
— | European | — | BSTOP | — |
| PSS009119 | — | — | 4,093 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009121 | — | — | 4,059 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009122 | — | — | 4,059 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009123 | — | — | 4,111 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009124 | — | — | 4,120 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009125 | — | — | 4,124 individuals | — | European | Poland (NE Europe) | UKB | — |